var title_f18_28_18880="Gomco clamp with safety pin";
var content_f18_28_18880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Safety pin on foreskin and Gomco clamp in position prior to excision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18880=[""].join("\n");
var outline_f18_28_18880=null;
var title_f18_28_18881="Treatment protocols for small-cell carcinoma of the lung";
var content_f18_28_18881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for small-cell carcinoma of the lung",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/28/18881/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18881/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18881/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18881/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18881/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/28/18881/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18881/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/28/18881/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18881/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/28/18881/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6926341\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with small-cell carcinoma of the lung.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with small-cell carcinoma of the lung. Additional regimens may be added over time, particularly as treatment for small-cell carcinoma of the lung evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with small-cell carcinoma of the lung. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121173046\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936901476\">",
"    <span class=\"h2\">",
"     Carboplatin plus etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef75586 \" href=\"UTD.htm?40/39/41597\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936901501\">",
"    <span class=\"h2\">",
"     Cisplatin (60 mg/m2) plus etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef58176 \" href=\"UTD.htm?11/9/11422\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936901526\">",
"    <span class=\"h2\">",
"     Cisplatin (80 mg/m2) plus etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef66855 \" href=\"UTD.htm?42/23/43389\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85693 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-1A9BDA5540-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18881=[""].join("\n");
var outline_f18_28_18881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6926341\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H121173046\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H936901476\">",
"      Carboplatin plus etoposide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H936901501\">",
"      Cisplatin (60 mg/m2) plus etoposide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H936901526\">",
"      Cisplatin (80 mg/m2) plus etoposide",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85693\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85693|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/39/41597\" title=\"table 1\">",
"      Carboplatin plus etoposide for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/9/11422\" title=\"table 2\">",
"      Cisplatin 60 plus etoposide for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/23/43389\" title=\"table 3\">",
"      Cisplatin 80 plus etoposide for small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_28_18882="Vacuum suction cups";
var content_f18_28_18882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Vacuum delivery suction cups",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     A: mushroom; B: bell.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aron Schuftan, MD. &copy; Aron Schuftan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18882=[""].join("\n");
var outline_f18_28_18882=null;
var title_f18_28_18883="Fatty cast";
var content_f18_28_18883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69603%7ENEPH%2F79604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69603%7ENEPH%2F79604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fatty cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing a fatty cast. The fat droplets (or globules) can be distinguished from red cells (which also have a round appearance) by their variable size (from much smaller to much larger than a red cell), dark outline, and \"Maltese cross\" appearance under polzarized light.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fatty cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 218px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing fatty cast under polarized light. The fat droplets have a characteristic \"Maltese cross\" appearance (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harvard Medical School.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18883=[""].join("\n");
var outline_f18_28_18883=null;
var title_f18_28_18884="Auranofin: Pediatric drug information";
var content_f18_28_18884=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Auranofin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"    see \"Auranofin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/27/9653?source=see_link\">",
"    see \"Auranofin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ridaura&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ridaura&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gold Compound",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"      see \"Auranofin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Initial: 0.1 mg/kg/day in 1-2 divided doses; usual maintenance: 0.15 mg/kg/day in 1-2 divided doses; maximum dose: 0.2 mg/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 6 mg/day in 1-2 divided doses; after 3 months may be increased to 9 mg/day in 3 divided doses; if still no response after 3 months at 9 mg/day, discontinue drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute: Reduce dose to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ridaura&reg;: 3 mg [gold 29%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F5205699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in tight, light-resistant containers at 15&deg;C to 30&deg;C.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of active stage of classic or definite rheumatoid or psoriatic arthritis in patients who do not respond to or tolerate other agents; adjunctive or alternative therapy for pemphigus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F138109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ridaura&reg; may be confused with Cardura&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F138107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia,pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea/loose stools, dysgeusia, dyspepsia, flatulence, glossitis, nausea, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria, proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, aplastic anemia, angioedema, corneal deposits, dysphagia, enterocolitis (ulcerative), fever, GI hemorrhage, gingivitis, gold bronchitis, hepatotoxicity, interstitial pneumonitis, jaundice, metallic taste, melena, neutropenia, pancytopenia, peripheral neuropathy, pure red cell aplasia.",
"     <b>",
"      Note:",
"     </b>",
"     Exfoliative dermatitis has been reported with other gold compounds.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Any history of gold-induced disorders including anaphylactoid reactions, necrotizing enterocolitis, exfoliative dermatitis, pulmonary fibrosis, bone marrow aplasia, or other severe hematologic disorders",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dose in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be associated with significant toxicity involving dermatologic, gastrointestinal, hematologic, pulmonary, renal, and hepatic systems",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; patient education is required; signs of gold toxicity include decrease in hemoglobin, leukocytes, granulocytes, and platelets; therapy should be discontinued if platelet count falls to &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , WBC &lt;4000, granulocytes &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     .  Dermatitis and lesions of the mucous membranes are common and may be serious; pruritus may precede the early development of a skin reaction; consider alternative therapy in patient with dermatitis.  Signs of GI toxicity include persistent diarrhea, stomatitis, and enterocolitis; avoid use in patients with prior inflammatory bowel disease.  May be associated with the development of cholestatic jaundice.  Consider alternative therapy in patients with hepatic impairment.  May be associated with interstitial fibrosis; monitor closely.  Renal toxicity ranges from mild proteinuria to nephrotic syndrome.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13273270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic (at least monthly): CBC with differential, platelet count, urinalysis for protein; baseline renal and liver function tests; skin and oral mucosa examinations; specific questioning for symptoms of pruritus, rash, stomatitis, or metallic taste",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1056707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gold: Normal: 0-0.1 mcg/mL (SI: 0-0.0064 micromoles/L); Therapeutic: 1-3 mcg/mL (SI: 0.06-0.18 micromoles/L); Urine &lt;0.1 mcg/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unknown, acts principally via immunomodulating effects and by decreasing lysosomal enzyme release; may alter cellular mechanisms by inhibiting sulfhydryl systems",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Therapeutic response may not be seen for 3-4 months after start of therapy",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Only about 20% to 25% of gold in a dose is absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 21-31 days (half-life dependent upon single or multiple dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 60% of absorbed gold is eliminated in urine while the remainder is eliminated in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/27/9653?source=see_link\">",
"      see \"Auranofin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify your physician of pruritus, sore mouth, indigestion, metallic taste; observe careful oral hygiene. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Metallic taste may indicate stomatitis",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12895 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18884=[""].join("\n");
var outline_f18_28_18884=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708624\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138065\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138066\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056705\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056698\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138047\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138031\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5205699\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056708\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138109\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138107\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056712\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056697\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056696\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298799\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218148\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138043\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13273270\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056704\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056707\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056695\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056710\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056711\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056703\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056713\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12895\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12895|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=related_link\">",
"      Auranofin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/27/9653?source=related_link\">",
"      Auranofin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_28_18885="HGPUC";
var content_f18_28_18885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Non-invasive high-grade papillary urothelial carcinoma (HGPUC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 178px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    At low power (A, 20x) HGPUC shows a pattern of disorder with easily recognizable architectural and cytologic variation. The papillae are frequently fused and branching. At high power (B-C, 40x) there is moderate to marked pleomorphism. The chromatin tends to be clumped, the nucleoli may be prominent, the thickness of the urothelium may vary considerably, and mitoses are often present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18885=[""].join("\n");
var outline_f18_28_18885=null;
var title_f18_28_18886="Diabetes mellitus type 2: Insulin treatment";
var content_f18_28_18886=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/28/18886/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18886/contributors\" id=\"au5149\">",
"       David K McCulloch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/28/18886/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18886/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/28/18886/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18886/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?18/28/18886?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      TYPE 2 DIABETES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Type 2 diabetes mellitus occurs when the pancreas (an organ in the abdomen) produces insufficient amounts of the hormone insulin",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     the body's tissues become resistant to normal or even high levels of insulin. This causes high blood glucose (sugar) levels, which can lead to a number of complications if untreated.",
"    </p>",
"    <p>",
"     People with type 2 diabetes require regular monitoring and ongoing treatment to maintain normal or near-normal blood sugar levels. Treatment includes lifestyle adjustments, self-care measures, and medications, which can minimize the risk of diabetes-related and cardiovascular complications (eg, heart attacks and strokes). Learning to manage diabetes is a process that continues over a lifetime. The diagnosis of diabetes can be overwhelming at the beginning; however, most people are able to lead normal lives and many patients become experts in their own care.",
"    </p>",
"    <p>",
"     This topic review discusses the role of insulin in blood sugar control for patients with type 2 diabetes. Separate topic reviews about other aspects of type 2 diabetes are also available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"      \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/60/6083?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"      \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      IMPORTANCE OF BLOOD SUGAR CONTROL IN TYPE 2 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Keeping blood sugar levels in control is one way to decrease the risk of complications related to type 2 diabetes. The most common complication of type 2 diabetes is heart disease, also known as macrovascular disease. Macro- means large, and vascular means vessels. Untreated heart disease increases the risk of heart attack.",
"    </p>",
"    <p>",
"     Individuals with type 2 diabetes are also at increased risk of developing microvascular (small vessel) disease of the eyes, kidneys, and nerves, which can result in blindness, kidney failure, foot ulcers requiring amputation, and impotence in men. Microvascular and macrovascular complications usually occur after many years of diabetes and are related to elevated levels of blood sugar over time. However, these complications may be present when type 2 diabetes is first diagnosed due to a delay in seeking medical care.",
"    </p>",
"    <p>",
"     One of the largest studies to examine the benefit of tight blood sugar control was the United Kingdom Prospective Diabetes Study (UKPDS). It demonstrated that strict glycemic control in patients with type 2 diabetes reduces the risk of microvascular disease. It is not clear if blood sugar control affects the risk of macrovascular complications [",
"     <a class=\"abstract\" href=\"UTD.htm?18/28/18886/abstract/1\">",
"      1",
"     </a>",
"     ]. Most randomized clinical trials have not demonstrated a beneficial effect of intensive therapy on macrovascular outcomes in type 2 diabetes, and data from the ACCORD trial suggest that lowering A1C to near normal may be unsafe in patients with a long history of diabetes who were at high risk for cardiovascular disease. However, other therapies are available to decrease the risk of macrovascular complications. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"      \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with type 2 diabetes need to monitor their blood sugar levels at home. This is especially true if the person uses a medication for diabetes that can cause low blood sugar levels (eg, insulin).",
"    </p>",
"    <p>",
"     Blood sugar control is often measured by checking the level before the first meal of the day (fasting). A normal fasting blood sugar is less than 100",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (5.6",
"     <span class=\"nowrap\">",
"      mmol/L),",
"     </span>",
"     although some people will have a different goal. A healthcare provider can help to determine this goal with the patient. Some people will need to test their blood sugar level before",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     after other meals during the day. The frequency of testing and blood sugar goals can change over time, so periodic visits to discuss these issues are important. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Blood sugar control can also be measured with a blood test called A1C. The A1C blood test measures the average blood sugar level during the past two to three months. The test is done by giving a small sample of blood from a vein or fingertip in a clinician's office. The goal A1C for most people with type 2 diabetes is less than 7 percent, which corresponds to an average blood sugar of 154",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (8.6",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     (",
"     <a class=\"graphic graphic_table graphicRef76310 \" href=\"UTD.htm?6/10/6316\">",
"      table 1",
"     </a>",
"     ). However, goal A1C levels in patients with type 2 diabetes should be tailored to the individual. As an example, the A1C goal should be set somewhat higher (8 percent) for frail older patients and those with a limited life expectancy. A healthcare provider can determine a person's individual A1C goal.",
"    </p>",
"    <p>",
"     The average blood sugar goal (150",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     or 8.3",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     is higher than the fasting blood sugar goal (100",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     or 5.6",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     for several reasons. Blood sugar levels increase after eating. The amount and speed of the increase depend upon the type and amount of food eaten at a particular meal. The increase also depends upon the type and dose of diabetes treatment(s) used and the person's activity level.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      How often to see your clinician",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most patients with type 2 diabetes meet with their healthcare provider every three to four months; blood sugar levels and medications, including insulin dosing, are reviewed at these visits, helping patients to fine-tune their diabetes control.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      TYPE 2 DIABETES TREATMENT OPTIONS",
"     </span>",
"    </p>",
"    <p>",
"     Most people who are newly diagnosed with type 2 diabetes are usually treated with a combination of diet, exercise, and an oral medication (eg, pills). Some oral medications (eg, metformin) improve the body's response to insulin. Other medications cause the body to produce more insulin. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A second medication may be added within the first two to three months if blood sugar control is not adequate. \"Adequate\" control is defined as an A1C level less than 7 percent for most people; insulin may be recommended early if the A1C remains elevated despite lifestyle changes and diabetes pills, especially if the A1C is higher than 8.5 percent.",
"    </p>",
"    <p>",
"     The need for a second medication is not uncommon [",
"     <a class=\"abstract\" href=\"UTD.htm?18/28/18886/abstract/2\">",
"      2",
"     </a>",
"     ]. Type 2 diabetes typically progresses over time, causing the body to produce less insulin and resist the action of insulin that is produced. In addition, it can be difficult for some people to follow the recommended diet, exercise, or treatment plan. Being diagnosed with a new medical problem or requiring a new medication can also change the body's needs for insulin, sometimes requiring a change in diabetes treatment. For example, when a person with type 2 diabetes takes steroids (eg, prednisone) for an asthma attack, the blood sugar levels increase. This usually requires a higher dose of diabetes medication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Oral medication plus insulin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people with type 2 diabetes require only oral medications for treatment. Other people will need to add insulin or another injectable medication because their blood sugar levels are not controlled. Using a combination of treatments (oral medication plus insulin) generally means that the person can take a lower dose of insulin, compared to if insulin treatment is used alone. There may also be a reduced risk of weight gain if combination therapy is used.",
"    </p>",
"    <p>",
"     Insulin is usually given once per day, either in the morning or at bedtime. Small insulin doses are generally recommended when treatment first begins; the dose is adjusted over days, weeks, and months, once the body's response to insulin treatment is known.",
"    </p>",
"    <p>",
"     To determine how and when to adjust the dose, the blood sugar level should be measured every morning before eating. If the value is consistently higher than 130",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (7.2",
"     <span class=\"nowrap\">",
"      mmol/L),",
"     </span>",
"     the clinician may recommend increasing the insulin dose. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Insulin alone",
"     </span>",
"     &nbsp;&mdash;&nbsp;Current recommendations are for most people with type 2 diabetes to be treated with metformin plus another medication such as insulin, as necessary. However, for a variety of reasons, some people are treated only with insulin. People taking insulin alone often require two injections of intermediate-acting insulin or one injection of long-acting insulin per day. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Types of insulin'",
"     </a>",
"     below and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"      \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If a long-acting insulin or a twice daily injection of intermediate-acting insulin is not adequate to control blood sugar levels, a more intensive insulin treatment regimen may be recommended. Intensive insulin treatment requires at least two injections of insulin per day, usually including a rapid-acting and long-acting insulin, or the use of an insulin pump (uncommon with type 2 diabetes). It also requires that the person monitor their blood sugar levels several times per day. This is discussed in greater detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link&amp;anchor=H6#H6\">",
"      \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\", section on 'Intensive insulin treatment'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      TYPES OF INSULIN",
"     </span>",
"    </p>",
"    <p>",
"     There are several types of insulin. These types are classified according to how quickly the insulin begins to work and how long it remains active:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Injectable insulin",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Rapid-acting (eg, insulin lispro [Humalog&reg;], insulin aspart [Novolog&reg;], and insulin glulisine [Apidra&reg;])",
"      </li>",
"      <li>",
"       Short-acting (eg, insulin regular)",
"      </li>",
"      <li>",
"       Intermediate-acting (eg, insulin NPH)",
"      </li>",
"      <li>",
"       Long-acting (eg, insulin glargine [Lantus&reg;], insulin detemir [Levemir&reg;])",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The various types of insulin can be used in combination to achieve around-the-clock blood sugar control.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Inhaled insulin",
"     </span>",
"     &nbsp;&mdash;&nbsp;An inhaled form of rapid-acting insulin was available for a short time but was discontinued in 2007. Other inhaled insulin preparations are in clinical trials but are not currently available.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      INJECTING INSULIN",
"     </span>",
"    </p>",
"    <p>",
"     Insulin cannot be taken in pill form. It is usually injected into the layer of fat under the skin (called subcutaneous injection).",
"    </p>",
"    <p>",
"     The following figure demonstrates the sites where insulin may be injected (",
"     <a class=\"graphic graphic_figure graphicRef74635 \" href=\"UTD.htm?9/33/9749\">",
"      figure 1",
"     </a>",
"     ). Patients as well as parents or partners should learn to draw up and inject insulin. The site also determines how quickly the insulin is absorbed. (See",
"     <a class=\"local\" href=\"#H18\">",
"      'Site of injection'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Drawing up insulin",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are many different types of syringes and needles, so it's best to get specific instructions for drawing up insulin from a healthcare provider. Basic information is provided in the table (",
"     <a class=\"graphic graphic_table graphicRef54094 \" href=\"UTD.htm?16/17/16668\">",
"      table 2",
"     </a>",
"     ). People who use an insulin pen should follow the instructions provided by the pen manufacturer and their clinician (see",
"     <a class=\"local\" href=\"#H15\">",
"      'Insulin pen injectors'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Before drawing up insulin, it is important to know the dose and type of insulin needed; persons using more than one type of insulin should calculate the total dose needed before drawing up their insulin. Some people, including children and those with difficulty seeing, may need assistance. Magnification and other assistive devices are available. People who have difficulty drawing up their insulin should discuss this with their clinician.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Injection angle",
"     </span>",
"     &nbsp;&mdash;&nbsp;Insulin is usually injected under the skin using a needle and syringe (",
"     <a class=\"graphic graphic_figure graphicRef80789 \" href=\"UTD.htm?9/58/10145\">",
"      figure 2",
"     </a>",
"     ). It is important to use the correct injection angle since injecting too deeply could deliver insulin to the muscle, where it is absorbed too quickly. On the other hand, injections that are too shallow are more painful and not absorbed well.",
"    </p>",
"    <p>",
"     The best angle for insulin injection depends upon a person's body type, injection site, and length of the needle used. A healthcare professional can help determine the right angle of injection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Injection technique",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following is a description of subcutaneous insulin injection.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Choose the site to inject (",
"       <a class=\"graphic graphic_figure graphicRef74635 \" href=\"UTD.htm?9/33/9749\">",
"        figure 1",
"       </a>",
"       ). It is not necessary to clean the skin with alcohol unless the skin is dirty.",
"      </li>",
"      <li>",
"       Pinch up a fold of skin and quickly insert the needle at a 90&ordm; angle (or other angle, as described above) (",
"       <a class=\"graphic graphic_figure graphicRef80789 \" href=\"UTD.htm?9/58/10145\">",
"        figure 2",
"       </a>",
"       ). Keep the skin pinched to avoid injecting insulin into the muscle.",
"      </li>",
"      <li>",
"       Push the plunger down completely to inject the insulin. Hold the syringe and needle in place for five seconds.",
"      </li>",
"      <li>",
"       Release the skin fold.",
"      </li>",
"      <li>",
"       Remove the needle from the skin.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If blood or clear fluid (insulin) is seen at the injection site, apply pressure to the area for five to eight seconds. The area should not be rubbed because this can cause the insulin to be absorbed too quickly.",
"    </p>",
"    <p>",
"     Needles and syringes should be used once and then thrown away; needles become dull quickly, potentially increasing the pain of injection. Used needles and syringes should not be included with regular household trash, but should instead be placed in a puncture-proof container (also known as a sharps container), available from most pharmacies or hospital supply stores.",
"    </p>",
"    <p>",
"     Some patients wonder about the safety of injecting insulin through their clothing. One small study examined the risks and benefits of this technique, and found that blood sugar control did not differ between the group that injected insulin through a single layer of clothing and those that injected directly into the skin [",
"     <a class=\"abstract\" href=\"UTD.htm?18/28/18886/abstract/3\">",
"      3",
"     </a>",
"     ]. There were no reports of infections in either group, although a few patients who injected through clothing reported blood stains on their clothing or bruises on the skin. People who are interested in using this technique should speak with their healthcare provider before trying it.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Insulin pen injectors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Insulin pen injectors are available and may be more convenient to carry and use when away from home. Most are approximately the size of a large writing pen and contain a disposable insulin cartridge and needle. Some types of insulin and some insulin mixtures are not available in cartridges, meaning pens may not be an option in some situations.",
"    </p>",
"    <p>",
"     Pens are especially useful for accurately injecting very small doses of insulin, and may be helpful for people with impaired vision. Pens are generally more expensive than traditional syringes and needles. A number of insulin pens are available, and the specific instructions for use of each type should be obtained from the manufacturer or a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      OTHER FACTORS AFFECTING INSULIN ACTION",
"     </span>",
"    </p>",
"    <p>",
"     Several factors can affect how injected insulin works.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Dose of insulin injected",
"     </span>",
"     &nbsp;&mdash;&nbsp;The dose of insulin injected affects the rate at which the body absorbs it. Larger doses of insulin may be absorbed more slowly than smaller doses.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Site of injection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Clinicians usually recommend rotating injection sites to minimize tissue irritation. When changing sites, it is important to keep in mind that insulin is absorbed at different rates in different areas of the body.",
"    </p>",
"    <p>",
"     Insulin is absorbed fastest from the abdominal area, slowest from the leg and buttock, and at an intermediate rate from the arm. This may vary with the amount of fat present; areas with more fat under the skin absorb insulin more slowly (",
"     <a class=\"graphic graphic_figure graphicRef74635 \" href=\"UTD.htm?9/33/9749\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     It is reasonable to use the same general area for injections given at the same time of the day. Sometimes abdominal injections, which are absorbed more quickly, are preferred before meals. Injection into the thigh or buttock may be best for the evening dose because the insulin will be absorbed more slowly during the night.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Smoking and physical activity",
"     </span>",
"     &nbsp;&mdash;&nbsp;Any factors that alter the rate of blood flow through the skin and fat will change insulin absorption. Smoking decreases blood flow. In contrast, factors that increase blood flow (such as exercise, saunas, hot baths, and massage of the injection site) increase insulin absorption and can result in hypoglycemia. Therefore, to avoid low blood sugar, insulin injections should be given after a bath or sauna. It is best to inject insulin into the arm or abdomen and wait 30 minutes before running. A lower dose of insulin may be recommended before or after exercise; this should be discussed with a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Time since opening the bottle",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most insulin remains potent and effective for up to a month after the bottle has been opened (if kept in the refrigerator between injections). However, the potency of intermediate and long acting insulin begins to decrease after 30 days. This can be a problem for people who require very small doses of insulin, for whom a bottle might last two months or more. It is advisable to start a new bottle at least every 30 days.",
"    </p>",
"    <p>",
"     For very rapid acting insulin used in pen injectors, it is acceptable to keep the pen injector at room temperature (in a purse or jacket pocket) for up to 14 days, provided that the pen is not exposed to temperature extremes. However, after 14 days, a new insulin cartridge or pen should be used, even if there is insulin left in the old cartridge.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Individual differences",
"     </span>",
"     &nbsp;&mdash;&nbsp;The same dose of the same type of insulin may have different effects in different people with diabetes. Some trial and error is usually necessary to find the ideal type(s) and dose of insulin and schedule for each person.",
"    </p>",
"    <p>",
"     Insulin needs often change over a person's lifetime. Changes in weight, diet, health conditions (including pregnancy), activity level, and occupation can have an impact on the amount of insulin needed to control blood sugar levels. Patients are often able to adjust their own insulin dose, but may require assistance in some situations. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"      \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      SPECIAL SITUATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Several special situations can complicate insulin treatment for a person with diabetes. With advance planning and careful calculation, these situations are less likely to cause serious difficulties. A healthcare provider can assist patients in handling these situations.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Eating out",
"     </span>",
"     &nbsp;&mdash;&nbsp;Eating out can be challenging since ingredients used, calorie and fat content, and portion sizes are usually different from meals prepared at home. Patients can estimate their insulin needs in several ways, including nutrition information from restaurants or a hand-held reference book.",
"    </p>",
"    <p>",
"     Hypo- and hyperglycemia can occur more easily in situations where new or different foods are eaten; thus patients should keep a fast-acting source of carbohydrates and blood glucose monitor on hand at all times. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"      \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients who undergo surgery may be instructed not to eat for 8 to 12 hours before their procedure. A healthcare provider can help to determine the dose and timing of insulin before and after the procedure, especially if the person will be unable to eat a normal diet afterwards.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Infections",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mild infections, such as a cold, sore throat, or urinary tract infection, can cause blood sugar levels to rise. In this situation, frequent telephone contact with a healthcare provider, careful blood sugar monitoring, and increasing the insulin dose are often recommended. It is important to drink an adequate amount of fluids while ill to avoid dehydration. Patients with nausea or vomiting may require medication to control their symptoms and avoid dehydration.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Travel",
"     </span>",
"     &nbsp;&mdash;&nbsp;Managing blood sugar levels and insulin treatment while traveling can be difficult, especially when traveling across multiple time zones. In addition, activity levels and diet are often different while traveling, making careful blood sugar monitoring essential. Patients should speak with their healthcare provider before traveling to develop a treatment plan. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link&amp;anchor=H21#H21\">",
"      \"Patient information: General travel advice (Beyond the Basics)\", section on 'Traveling with medical conditions'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H27\">",
"     <span class=\"h1\">",
"      STAYING MOTIVATED WITH TYPE 2 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Living with diabetes can be very demanding and some patients lose motivation over time. Healthcare providers can provide tips and encouragement to help patients stay on track. Helpful information and support is also available from the American Diabetes Association (ADA) at (800)-DIABETES (800-342-2383) and at",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     .",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2518317344\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14371906\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=see_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=see_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14531?source=see_link\">",
"      Patient information: Low blood sugar in people with diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/2/36898?source=see_link\">",
"      Patient information: Diabetic ketoacidosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25699?source=see_link\">",
"      Patient information: Hyperosmolar nonketotic coma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/47/6899?source=see_link\">",
"      Patient information: Should I switch to an insulin pump? (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14371978\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/60/6083?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=see_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=see_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20794?source=see_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15353?source=see_link\">",
"      Inhaled insulin therapy in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26233?source=see_link\">",
"      Management of diabetes mellitus in hospitalized patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Canadian Diabetes Associates",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.ca/\">",
"      www.diabetes.ca",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Juvenile Diabetes Research Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.jdrf.org/\">",
"      www.jdrf.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       US Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/diabetes\">",
"      www.cdc.gov/diabetes",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?18/28/18886/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 15, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?18/28/18886?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18886/abstract/1\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18886/abstract/2\">",
"      Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18886/abstract/3\">",
"      Fleming DR, Jacober SJ, Vandenberg MA, et al. The safety of injecting insulin through clothing. Diabetes Care 1997; 20:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18886/abstract/4\">",
"      Yki-J&auml;rvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18886/abstract/5\">",
"      Taylor R, Davies R, Fox C, et al. Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study. Diabetes Care 2000; 23:1612.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f18_28_18886=[""].join("\n");
var outline_f18_28_18886=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           TYPE 2 DIABETES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           IMPORTANCE OF BLOOD SUGAR CONTROL IN TYPE 2 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           TYPE 2 DIABETES TREATMENT OPTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           TYPES OF INSULIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           INJECTING INSULIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           OTHER FACTORS AFFECTING INSULIN ACTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           SPECIAL SITUATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H27\">",
"           STAYING MOTIVATED WITH TYPE 2 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/33/9749\" title=\"figure 1\">",
"           Insulin injection sites PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/58/10145\" title=\"figure 2\">",
"           Insulin injection PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?6/10/6316\" title=\"table 1\">",
"           A1C and blood sugar PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?16/17/16668\" title=\"table 2\">",
"           Drawing up insulin PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f18_28_18887="Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma";
var content_f18_28_18887=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/28/18887/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18887/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18887/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/28/18887/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18887/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/28/18887/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18887/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/28/18887/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small lymphocytic lymphoma (SLL) is a mature (peripheral) B cell neoplasm characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin. It is considered to be synonymous (ie, one disease at different stages) to chronic lymphocytic leukemia (CLL) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/1\">",
"     1",
"    </a>",
"    ]. The malignant cells seen in SLL and CLL have identical pathologic and immunophenotypic features. A distinction between these two diagnoses is generally made based upon the patient's clinical presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=see_link\">",
"     \"Epidemiology and clinical manifestations of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The pathologic features, diagnosis, and differential diagnosis of SLL will be reviewed here. The pathophysiology, molecular biology, cytogenetic abnormalities, and treatment of SLL are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link\">",
"      \"Pathophysiology and genetic features of chronic lymphocytic leukemia\"",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CLL/SLL",
"    comprises 90 percent of chronic lymphocytic leukemias in the United States and Europe. Less than 10 percent of patients present with a non-leukemic picture having only nodal involvement (ie, SLL); this presentation accounts for less than 5 percent of all non-Hodgkin lymphomas. However, most patients with SLL at presentation ultimately develop bone marrow and blood infiltration (CLL).",
"   </p>",
"   <p>",
"    The median age at diagnosis is 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately 80 percent have stage IV disease and 70 to 90 percent have bone marrow involvement at diagnosis (",
"    <a class=\"graphic graphic_table graphicRef64113 \" href=\"UTD.htm?34/39/35453\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H29#H29\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with SLL present with painless generalized lymphadenopathy, which has frequently been present for several years. B symptoms occur in a minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/2\">",
"     2",
"    </a>",
"    ]. Both hepatosplenomegaly and extranodal infiltrates may be seen.",
"   </p>",
"   <p>",
"    The peripheral blood in patients with SLL may be normal or reveal only a mild lymphocytosis; by definition, patients with SLL have an absolute lymphocyte count of",
"    <span class=\"nowrap\">",
"     &lt;5000/microL",
"    </span>",
"    at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/1\">",
"     1",
"    </a>",
"    ]. A serum paraprotein or hypogammaglobulinemia is found in 20 and 40 percent of cases, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;This discussion will focus on the morphologic, immunophenotypic, and genetic findings on lymph node biopsy. Abnormalities seen in the peripheral blood and on bone marrow aspirate and biopsy are identical to those seen in chronic lymphocytic leukemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\", section on 'Pathologic features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lymph node histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lymph node infiltrate of",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    is composed predominantly of small lymphocytes with condensed chromatin, round nuclei, and, occasionally, a small nucleolus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Larger lymphoid cells (prolymphocytes and paraimmunoblasts) with more prominent nucleoli and dispersed chromatin are always present (",
"    <a class=\"graphic graphic_picture graphicRef75466 \" href=\"UTD.htm?35/21/36182\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef51681 \" href=\"UTD.htm?27/52/28486\">",
"     picture 2",
"    </a>",
"    ). These larger lymphoid cells are usually clustered in pseudofollicles (proliferation centers), the presence of which is taken to be pathognomonic of",
"    <span class=\"nowrap\">",
"     CLL/SLL.",
"    </span>",
"   </p>",
"   <p>",
"    In",
"    some cases, the cells show moderate nuclear irregularity, which can lead to a differential diagnosis of mantle cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Occasional cases show plasmacytoid differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunophenotypic analysis is a key component to the diagnosis of SLL. While SLL lymphocytes are described as mature-appearing cells, they are, in fact, immature both functionally and developmentally. There are three major characteristic immunophenotypic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expression of B cell associated antigens including CD19, CD20, and CD23. Expression of CD20 is usually weak. Expression of CD21 and CD24 can be seen, but is not required for diagnosis.",
"     </li>",
"     <li>",
"      Expression of CD5, a T cell associated antigen.",
"     </li>",
"     <li>",
"      Low levels of surface membrane immunoglobulin (ie, SmIg weak). The immunoglobulin is most often IgM or both IgM and IgD, and only a single immunoglobulin light chain is expressed (ie, either kappa or lambda but not both), confirming the clonal nature of these cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, SLL cells express HLA-DR and are usually negative for cyclin D1 and CD10. FMC7, CD22, and CD79b are also commonly negative or weakly expressed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/1\">",
"     1",
"    </a>",
"    ]. Cytoplasmic immunoglobulin is detectable in about 5 percent of the cases. Approximately 40 percent of the cases express CD38 on &gt;30 percent of the cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link&amp;anchor=H14#H14\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\", section on 'CD38'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin genes are clonally rearranged [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/8\">",
"     8",
"    </a>",
"    ]. In early studies, most cases (75 percent) of SLL did not show somatic mutation of their variable (V) regions, suggesting that they corresponded to a cell that had not yet undergone antigen selection in the germinal center [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/9\">",
"     9",
"    </a>",
"    ]. However, more recent reports have found V region mutations in up to 40 percent of patients, consistent with exposure to the germinal center.",
"   </p>",
"   <p>",
"    About 50 percent of patients with",
"    <span class=\"nowrap\">",
"     B-SLL/CLL",
"    </span>",
"    have abnormal karyotypes, but none is diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/10\">",
"     10",
"    </a>",
"    ]. Examples of common abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trisomy 12 is present in about 20 to 40 percent of the cases with cytogenetic abnormalities, and correlates with atypical histology and an aggressive clinical course [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/6,11,12\">",
"       6,11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormalities of 13q are seen in up to 25 percent of cases and are associated with long survival.",
"     </li>",
"     <li>",
"      t(11;14) with the cyclin D1 (BCL-1) gene rearrangement has been described but many of these cases may be examples of leukemic mantle cell lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Rare cases of B-CLL with cyclin D1 gene rearrangement",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cyclin D1 overexpression have been reported; these tend to pursue an unusually aggressive clinical course distinct from typical B-CLL [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormalities of 11q23 are found in a small subset of cases, and are associated with lymphadenopathy and an aggressive course [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other abnormalities that may be seen include deletions of 11q and 6q, and trisomy 3 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/19-23\">",
"       19-23",
"      </a>",
"      ]. The patients with 6q abnormalities have circulating prolymphocytoid cells [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/24\">",
"       24",
"      </a>",
"      ]. Rare tumors with the t(11;18) may represent unusual leukemic variants of extranodal marginal zone lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Deep sequencing studies of CLL have revealed recurrent mutations in the NOTCH1, XPO1, MYD88, and KLHL6 genes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/26\">",
"       26",
"      </a>",
"      ]. It is not yet clear if SLL will share these same sets of mutations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link&amp;anchor=H12#H12\">",
"       \"Pathophysiology and genetic features of chronic lymphocytic leukemia\", section on 'Molecular genetics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chromosomal changes seen in chronic lymphocytic leukemia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link\">",
"     \"Pathophysiology and genetic features of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SLL is made based upon the evaluation of an excisional lymph node biopsy along with the analysis of a bone marrow biopsy and aspirate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Lymph node and tissue biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SLL is a neoplasm of monomorphic, small round B-lymphocytes, involving the peripheral blood, bone marrow, and lymph nodes. SLL is a tissue infiltrate with the morphology and immunophenotype of chronic lymphocytic leukemia (CLL) in a patient with an insufficient number of circulating leukemia cells to fulfill the criteria for CLL. Specifically, patients with lymphadenopathy without cytopenias and an absolute peripheral B lymphocyte count that is less than",
"    <span class=\"nowrap\">",
"     5000/microL",
"    </span>",
"    [5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L]",
"    </span>",
"    are given the diagnosis of SLL rather than CLL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=see_link\">",
"     \"Epidemiology and clinical manifestations of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for SLL includes other small B cell lymphoproliferative disorders such as mantle cell lymphoma, hairy cell leukemia, and follicular lymphoma. Of particular importance, SLL can convert to diffuse large B cell lymphoma (Richter's transformation) (",
"    <a class=\"graphic graphic_table graphicRef81166 \" href=\"UTD.htm?27/58/28588\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mantle cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLL cells can show moderate nuclear irregularity much like those seen in mantle cell lymphoma (MCL) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In addition, MCL can have a leukemic phase that may mimic CLL. Like the malignant cells of SLL, MCL tumors coexpress CD5 and CD20. However, the neoplastic cells of MCL stain strongly for cyclin D1 and surface membrane immunoglobulin (SmIg), have a t(11;14) chromosomal abnormality, and are negative for CD23. In contrast, the malignant cells in",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    are typically negative for cyclin D1 and are often CD23 positive.",
"   </p>",
"   <p>",
"    Some cases of",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    may be CD23-, and MCL can be CD23+; in such tumors, stains for cyclin D1 take on particular importance. Rare cases of CLL with cyclin D1 gene rearrangement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyclin D1 overexpression have been reported; these tend to pursue an unusually aggressive clinical course distinct from typical B-CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The presence of clear-cut proliferation centers excludes the diagnosis of MCL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hairy cell leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hairy cell leukemia (HCL) is another small B cell lymphoproliferative disorder that can present with splenomegaly and cytopenias. The abnormal B cell in SLL usually stains positively for CD5, an antigen rarely expressed in HCL. Conversely, HCL is usually positive for CD103, an antigen rarely if ever expressed in SLL. In marrow biopsies, SLL often is present in a nodular pattern, whereas HCL always involves the marrow in an interstitial pattern without nodularity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=see_link\">",
"     \"Clinical features and diagnosis of hairy cell leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\", section on 'Bone marrow aspirate and biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Follicular lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with follicular lymphoma (FL) can present in a similar fashion to SLL with diffuse painless peripheral adenopathy, often waxing and waning over long periods of time. In addition, the tumors cells are small in size. However, one of the most notable morphologic features of FL is its nodular growth pattern, which is not seen in SLL. On occasion, proliferation centers are so prominent in",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    that involved lymph nodes can take on a mottled \"pseudo-nodular\" appearance. However, these two entities differ in their immunophenotype. In contrast to FL, cells in SLL do not express CD10. (See",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"      \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Histologic transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;CLL/SLL",
"    can convert to diffuse large B cell lymphoma (Richter's transformation) (",
"    <a class=\"graphic graphic_picture graphicRef53282 \" href=\"UTD.htm?11/54/12135\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. Affected patients usually present with rapidly growing masses, elevated serum LDH, and B symptoms and generally have short survivals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18887/abstract/4\">",
"     4",
"    </a>",
"    ]. For patients whose disease undergoes transformation, terminal complications are the result of marrow replacement, immunodeficiency complicated by infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypersplenism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=see_link\">",
"     \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other patients transform to a condition that resembles B cell prolymphocytic leukemia (B-PLL). These patients often develop very high white cell counts and massive splenomegaly, and also have a poor prognosis. This diagnosis should be made with caution if based merely on an increase in prolymphocytes in the peripheral blood, as transient increases in these cells can be seen on occasion in patients with clinically stable",
"    <span class=\"nowrap\">",
"     CLL/SLL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20358?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small lymphocytic lymphoma (SLL) is a mature (peripheral) B cell neoplasm characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin. It is considered to be identical (ie, one disease at different stages) to chronic lymphocytic leukemia (CLL). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with SLL present with painless generalized lymphadenopathy, often waxing and waning over long periods of time. The peripheral blood may be normal or reveal only a mild lymphocytosis. Circulating malignant cells have an identical morphology and immunophenotype to those of CLL (",
"      <a class=\"graphic graphic_picture graphicRef54469 \" href=\"UTD.htm?22/17/22803\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef63637 \" href=\"UTD.htm?24/1/24600\">",
"       picture 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link&amp;anchor=H3#H3\">",
"       \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\", section on 'Morphology'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunophenotype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The histopathologic lymph node findings in SLL and CLL are identical and consist of a diffusely effaced nodal architecture with an infiltrate composed of mostly mature-appearing, small lymphocytes, with an admixture of prolymphocytes and paraimmunoblasts. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Lymph node histology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunophenotypic analysis reveals a clonal population of cells that express B cell associated antigens, the T cell associated antigen CD5, and low levels of surface immunoglobulin. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunophenotype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of SLL is made based upon the evaluation of an excisional lymph node biopsy along with the analysis of a bone marrow biopsy and aspirate. Patients with lymphadenopathy without cytopenias and an absolute peripheral B lymphocyte count that is less than",
"      <span class=\"nowrap\">",
"       5000/microL",
"      </span>",
"      [5 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L]",
"      </span>",
"      are given the diagnosis of SLL rather than CLL. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of SLL includes other small B cell lymphoproliferative disorders such as mantle cell lymphoma, hairy cell leukemia, and follicular lymphoma. Of particular importance, a percentage of cases will transform into more aggressive lymphomas (",
"      <a class=\"graphic graphic_table graphicRef81166 \" href=\"UTD.htm?27/58/28588\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/2\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     Lennert K. Malignant lymphomas other than Hodgkin's disease, Springer-Verlag, New York 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/4\">",
"      Ben-Ezra J, Burke JS, Swartz WG, et al. Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases. Blood 1989; 73:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/5\">",
"      Perry DA, Bast MA, Armitage JO, Weisenburger DD. Diffuse intermediate lymphocytic lymphoma. A clinicopathologic study and comparison with small lymphocytic lymphoma and diffuse small cleaved cell lymphoma. Cancer 1990; 66:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/6\">",
"      Bonato M, Pittaluga S, Tierens A, et al. Lymph node histology in typical and atypical chronic lymphocytic leukemia. Am J Surg Pathol 1998; 22:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/7\">",
"      Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/8\">",
"      Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/9\">",
"      Aoki H, Takishita M, Kosaka M, Saito S. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenstr&ouml;m's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood 1995; 85:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/10\">",
"      Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/11\">",
"      Knuutila S, Elonen E, Teerenhovi L, et al. Trisomy 12 in B cells of patients with B-cell chronic lymphocytic leukemia. N Engl J Med 1986; 314:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/12\">",
"      Juliusson G, Merup M. Cytogenetics in chronic lymphocytic leukemia. Semin Oncol 1998; 25:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/13\">",
"      Tsujimoto Y, Yunis J, Onorato-Showe L, et al. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 1984; 224:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/14\">",
"      Croce CM, Tsujimoto Y, Erikson J, Nowell P. Chromosome translocations and B cell neoplasia. Lab Invest 1984; 51:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/15\">",
"      Yang WI, Zukerberg LR, Motokura T, et al. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994; 145:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/16\">",
"      Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994; 84:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/17\">",
"      Zhu Y, Monni O, El-Rifai W, et al. Discontinuous deletions at 11q23 in B cell chronic lymphocytic leukemia. Leukemia 1999; 13:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/18\">",
"      Sembries S, Pahl H, Stilgenbauer S, et al. Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion. Blood 1999; 93:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/19\">",
"      Correlation of chromosome abnormalities with histologic and immunologic characteristics in non-Hodgkin's lymphoma and adult T cell leukemia-lymphoma. Fifth International Workshop on Chromosomes in Leukemia-Lymphoma. Blood 1987; 70:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/20\">",
"      Juneja S, Lukeis R, Tan L, et al. Cytogenetic analysis of 147 cases of non-Hodgkin's lymphoma: non-random chromosomal abnormalities and histological correlations. Br J Haematol 1990; 76:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/21\">",
"      Offit K, Jhanwar SC, Ladanyi M, et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer 1991; 3:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/22\">",
"      Schouten HC, Sanger WG, Weisenburger DD, et al. Chromosomal abnormalities in untreated patients with non-Hodgkin's lymphoma: associations with histology, clinical characteristics, and treatment outcome. The Nebraska Lymphoma Study Group. Blood 1990; 75:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/23\">",
"      Yunis JJ, Oken MM, Kaplan ME, et al. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 1982; 307:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/24\">",
"      Offit K, Louie DC, Parsa NZ, et al. Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q21q23). Blood 1994; 83:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/25\">",
"      Levine EG, Arthur DC, Machnicki J, et al. Four new recurring translocations in non-Hodgkin lymphoma. Blood 1989; 74:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/26\">",
"      Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/27\">",
"      Hubbard SM, Chabner BA, DeVita VT Jr, et al. Histologic progression in non-Hodgkin's lymphoma. Blood 1982; 59:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/28\">",
"      Foucar K, Rydell RE. Richter's syndrome in chronic lymphocytic leukemia. Cancer 1980; 46:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/29\">",
"      Long JC, Aisenberg AC. Richter's syndrome. A terminal complication of chronic lymphocytic leukemia with distinct clinicopathologic features. Am J Clin Pathol 1975; 63:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/30\">",
"      Robertson LE, Pugh W, O'Brien S, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol 1993; 11:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18887/abstract/31\">",
"      Trump DL, Mann RB, Phelps R, et al. Richter's syndrome: diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia. A report of five cases and review of the literature. Am J Med 1980; 68:539.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4746 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18887=[""].join("\n");
var outline_f18_28_18887=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lymph node histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Histologic transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4746\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4746|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/21/36182\" title=\"picture 1\">",
"      CLL proliferation centers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/52/28486\" title=\"picture 2\">",
"      CLL lymph node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/54/12135\" title=\"picture 3\">",
"      Richters transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/17/22803\" title=\"picture 4\">",
"      CLL smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/1/24600\" title=\"picture 5\">",
"      CLL marrow low",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4746|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/39/35453\" title=\"table 1\">",
"      Presenting features NHL types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 2\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/58/28588\" title=\"table 3\">",
"      DDx SLL path",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=related_link\">",
"      Clinical features and diagnosis of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20358?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=related_link\">",
"      Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=related_link\">",
"      Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=related_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=related_link\">",
"      Pathophysiology and genetic features of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=related_link\">",
"      Staging and prognosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_28_18888="Clinical features and complications of status epilepticus in children";
var content_f18_28_18888=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and complications of status epilepticus in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/28/18888/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18888/contributors\">",
"     Angus Wilfong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/28/18888/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18888/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/28/18888/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18888/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/28/18888/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common medical neurologic emergency in childhood, status epilepticus (SE) is a serious and often life-threatening medical emergency.",
"   </p>",
"   <p>",
"    The definition, pathophysiology, classification, risk factors, and outcome of status epilepticus in children are reviewed here. Treatment of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"     \"Management of status epilepticus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Classification of Epileptic Seizures defines status epilepticus (SE) as a seizure that lasts for a sufficient length of time (30 minutes or longer in most studies) or is repeated frequently enough that the individual does not regain consciousness between seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This definition is arbitrary, and other studies have suggested that the definition should include patients with seizures of shorter duration (eg, over 10 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. For the purpose of treatment decisions, this shorter time definition has merit. One study found that a convulsive seizure lasting more than five minutes has a high risk of lasting 30 minutes or more [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/5\">",
"     5",
"    </a>",
"    ]. Also, treatment delay is associated with delayed treatment response [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the outcome is worse with more prolonged seizures, suggesting that the standard definition be retained for epidemiologic studies. In one study, for example, 226 cases of SE (91 children and 135 adults) were compared to 81 patients (31 children and 50 adults) with seizure episodes of 10 to 29 minutes duration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/8\">",
"     8",
"    </a>",
"    ]. Both mortality (19 versus 2.6 percent) and the need for anticonvulsant treatment to control and stop seizure activity (93 versus 57 percent) were greater in the group with SE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Electrical (subclinical) seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures recognized only on the electroencephalogram (EEG) are referred to as subclinical seizures and can continue after abnormal clinical activity has been stopped by anticonvulsant medication [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/9\">",
"     9",
"    </a>",
"    ]. Some classifications have considered these seizures to be sustained seizures in comatose patients, whether or not the ictal discharges seen on EEG were accompanied by subtle convulsive activity, such as tonic eye deviation or rhythmic twitching of part of an extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Controversy exists about the types of EEG patterns that should be considered ictal in patients without clinical manifestations. Some experts argue that periodic epileptiform activity, a common finding in severe hypoxic-ischemic encephalopathy, should be considered ictal and treated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, most epileptologists consider this activity to be interictal and would not increase anticonvulsant therapy solely on the basis of this type of discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/12\">",
"     12",
"    </a>",
"    ]. In contrast, actual electrographic seizures, which are familiar to the experienced electroencephalographer, should be treated in the absence of concomitant clinical behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Status epilepticus (SE) occurs because of failure of the normal mechanisms that limit the spread and recurrence of isolated seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. Failure occurs because excitation is excessive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inhibition is ineffective. Multiple mechanisms probably are involved.",
"   </p>",
"   <p>",
"    Glutamate is the major amino acid excitatory neurotransmitter in the brain. Its role in the pathogenesis of SE was suggested by an outbreak of illness caused by eating mussels contaminated with domoic acid, an analogue of glutamate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/14\">",
"     14",
"    </a>",
"    ]. Some affected individuals had prolonged seizures thought to be caused by excessive activation of excitatory amino acid receptors. Other excitatory neurotransmitters that contribute to SE include aspartate and acetylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the brain, and antagonists to its effects or alternations in its metabolism in the substantia nigra may contribute to SE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/15\">",
"     15",
"    </a>",
"    ]. In a rat model, for example, the rate of GABA synthesis in the substantia nigra declined significantly during induced SE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/16\">",
"     16",
"    </a>",
"    ]. Other inhibitory mechanisms include the calcium ion-dependent potassium ion current and blockage of N-methyl-d-aspartate (NMDA) channels by magnesium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neuronal loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Though the outcome of SE generally is favorable in the absence of an underlying neurologic condition, minor amounts of neuronal loss are thought to occur with every episode, particularly if prolonged. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Outcome'",
"    </a>",
"    below.) Over time, this loss may accumulate and lead to significant impairment.",
"   </p>",
"   <p>",
"    Disturbance of the NMDA channels appears to be an important mechanism of neuronal injury in SE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/13\">",
"     13",
"    </a>",
"    ]. When neurons are depolarized, calcium enters the cell through NMDA channels and causes injury or death. Other possible contributing factors include hypoxia, excessive release of excitatory amino acids and calcium, increases of various proteins, including those that promote apoptosis (programmed cell death), alterations in receptor populations, and, in the temporal lobe, sprouting of dentate granule cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Abnormalities on magnetic resonance imaging (MRI) and release of the neuron-specific enolase are markers of neuronal damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     MR imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal radiologic changes are not uncommon occurrences during and after focal SE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Some of these abnormalities are related to the underlying cause of the patient's seizures and include focal cortical dysplasias and areas of gliosis.",
"   </p>",
"   <p>",
"    Other MRI changes appear to be a result of the acute seizure activity, and include mild edema, decreased attenuation with effacement of sulci, and loss of gray-white differentiation. These can resemble changes seen in acute ischemic stroke; however, the abnormalities do not conform to vascular territories, but to the electroencephalogram (EEG) localization of the seizures. In one study of two adults and a four-year-old boy, the MRI findings were consistent with those of cytotoxic and vasogenic edema, hyperperfusion of the epileptogenic region, and alteration of the leptomeningeal blood-brain barrier, the latter manifest by leptomeningeal enhancement on the postcontrast MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/20\">",
"     20",
"    </a>",
"    ]. The acute lesions in this study were followed by regional brain atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Neuron-specific enolase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enolase is an enzyme that is part of the glycolytic pathway for the conversion of glucose to pyruvate. It exists in three dimeric forms: alpha, beta, and gamma. The gamma isoform is exclusive to neurons and is termed neuron-specific enolase (NSE). This enzyme converts 2-phosphoglycerate to phosphoenolpyruvate. It is released into the cerebrospinal fluid (CSF) and blood after the occurrence of stroke and anoxia.",
"   </p>",
"   <p>",
"    NSE correlates with the extent and duration of ischemia in animal models of stroke and the outcome in humans, including neonates, with hypoxic-ischemic encephalopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/21\">",
"     21",
"    </a>",
"    ]. Increases after a single seizure have been reported by some researchers, but it is more predictably increased in serum and CSF after SE, particularly complex partial status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Absence status is considered a relatively benign condition. However, serum NSE may be increased in children with prolonged absence status [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/24\">",
"     24",
"    </a>",
"    ], which may be followed by permanent cognitive impairment in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual classification of SE is similar to that used for individual seizures and includes four major types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Simple partial &mdash; Continuous or repeated focal motor or sensory seizures without impaired consciousness.",
"     </li>",
"     <li>",
"      Complex partial &mdash; Continuous or repeated episodes of focal motor, sensory, or cognitive symptoms with impaired consciousness. This is also called nonconvulsive SE. In some patients the clinical manifestations of seizure activity are subtle and not apparent to the clinician.",
"     </li>",
"     <li>",
"      Generalized convulsive including tonic-clonic, tonic, and clonic &mdash; Always associated with loss of consciousness.",
"     </li>",
"     <li>",
"      Absence status epilepticus &mdash; Generalized seizure activity, characterized clinically by altered awareness, but not necessarily unconsciousness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Numerous less common but important forms, including myoclonic and pseudoseizures or psychogenic seizures, also occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"     \"Management of status epilepticus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonepileptic seizures &mdash; These seizures (also known as psychogenic seizures) usually are excluded from studies of SE but are a common problem, particularly in teenagers [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/26\">",
"       26",
"      </a>",
"      ]. These individuals often present to emergency departments because of recurrent episodes of abnormal behavior or prolonged seizures, which are unresponsive to standard anticonvulsant medications. The seizures typically occur in patients with affective and anxiety disorders and a family history of seizures. The clinical characteristics of pseudoseizures and their differentiation from true epileptic seizures are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=see_link\">",
"       \"Nonepileptic paroxysmal disorders in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the clinical classification, SE in children can be classified broadly into categories based on etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic, acute or remote &mdash; Acute symptomatic causes include infection, hypoxia, glucose and electrolyte imbalance, trauma, and hemorrhage or stroke. Remote symptomatic refers to seizures caused by an insult earlier in life, such as perinatal hypoxic-ischemic injury, trauma, infection, or a congenital brain malformation.",
"     </li>",
"     <li>",
"      Idiopathic or cryptogenic &mdash; No known or identifiable cause.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study classified 394 cases of SE in children aged one month to 16 years and found important age-related differences [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/27\">",
"     27",
"    </a>",
"    ]. SE was classified as reactive (due to fever), acute symptomatic, remote symptomatic, cryptogenic or idiopathic, and progressive encephalopathy in 29, 28, 24, 15, and 5 percent, respectively. SE occurred more commonly in young children, with more than 40 percent occurring in those younger than two years of age. More than 80 percent of the younger children had SE of febrile or acute symptomatic etiology, whereas older children were more likely to be in the cryptogenic or remote symptomatic categories. Older children also were more likely to be neurologically abnormal (55 versus 21 percent) and to have a history of seizures (64 versus 20 percent) compared to those younger than two years of age. Similar trends are reported in another population-based case series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated incidence of childhood status epilepticus (SE) is between 17 to 23 episodes per 100,000 per year [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. SE can be a complication of acute illness such as encephalitis, or can occur as a manifestation of epilepsy. Incidence rates, causes, and prognosis vary substantially by age. The highest incidence is in the first year of life. Febrile status epilepticus is the most common etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/30\">",
"     30",
"    </a>",
"    ]. About 60 percent of children are neurologically healthy prior to the first episode of SE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for SE have been best defined in the setting of established epilepsy. Between 10 and 20 percent of children with epilepsy will have at least one episode of SE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/31\">",
"     31",
"    </a>",
"    ]. SE occurs as the first seizure in 12 percent of children with epilepsy. Patients with partial seizures that tend to occur in clusters (three or more within 24 hours, with return to baseline between seizures) have a higher incidence of SE compared with those who do not cluster (47 versus 13 percent, in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/32\">",
"     32",
"    </a>",
"    ]. Other risk factors for SE in children with symptomatic epilepsy include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Focal background EEG abnormalities",
"     </li>",
"     <li>",
"      Partial seizures with secondary generalization",
"     </li>",
"     <li>",
"      Occurrence of SE as the first seizure",
"     </li>",
"     <li>",
"      Generalized abnormalities on neuroimaging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prospective, community-based cohort study of 613 children with newly diagnosed epilepsy, 56 (9 percent) had one or more episodes of SE by the time the diagnosis of epilepsy was established [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/2\">",
"     2",
"    </a>",
"    ]. Similarly, SE was the first presentation of epilepsy in 10 percent of 1382 children in a database of children with new onset seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/30\">",
"     30",
"    </a>",
"    ]. After a median follow-up of eight years, 18 of the 56 (32 percent) children in the first cohort had at least one recurrence of SE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/34\">",
"     34",
"    </a>",
"    ]. A first episode of SE occurred in an additional 40 patients. Independent risk factors for SE were [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/28,34\">",
"     28,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of prior SE",
"     </li>",
"     <li>",
"      Young age (one year or less) at onset",
"     </li>",
"     <li>",
"      Symptomatic etiology of epilepsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in rodent models have shown that genetic influences are important in the susceptibility to SE. As an example, both latencies to kainate-induced seizures and SE and the extent of excitotoxic damage to the hippocampus after recurrent seizures vary among different strains of rodents because of polygenic influences [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human twin studies also have shown a genetic predisposition for SE. One report examined 39 pairs of twins with a history of seizures in at least one twin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/37\">",
"     37",
"    </a>",
"    ]. Seizure and SE concordance rates were significantly higher in the 13 pairs of monozygotic twins compared with the 26 pairs of dizygotic twins (0.38 versus 0.00). The concordance rate for SE was highest in the monozygotic twins who also were concordant for seizures (0.58). The nature of the genetic factor(s) is yet to be elucidated.",
"   </p>",
"   <p>",
"    Some genetic syndromes (eg, Dravet syndrome, generalized epilepsy with febrile seizures plus or GEFS+, Angelman syndrome) tend to present with recurrent episodes of status epilepticus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;SE may occur in the setting of underlying, premorbid epilepsy or as the first manifestation of epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/30\">",
"     30",
"    </a>",
"    ]. Virtually any cause of epilepsy may have a first presentation with SE.",
"   </p>",
"   <p>",
"    SE may also be an acute symptom of medical or neurologic disease. The more common examples of the latter include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/30,38\">",
"     30,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Central nervous system infections",
"     </li>",
"     <li>",
"      Acute hypoxic ischemic insult",
"     </li>",
"     <li>",
"      Metabolic disease (eg, hypoglycemia, inborn error of metabolism)",
"     </li>",
"     <li>",
"      Electrolyte imbalance",
"     </li>",
"     <li>",
"      Traumatic brain injury",
"     </li>",
"     <li>",
"      Drugs, intoxication, poisoning",
"     </li>",
"     <li>",
"      Cerebrovascular event",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Febrile infection-related epilepsy syndrome (FIRES) refers to a presentation with refractory status epilepticus in the setting of a prodromal febrile illness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Other names for this entity include &ldquo;new-onset refractory status epilepticus&rdquo; (NORSE) and acute encephalitis with refractory repetitive partial seizures (AERRPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/41\">",
"     41",
"    </a>",
"    ]. This has been described in adults as well as children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link&amp;anchor=H3#H3\">",
"     \"Status epilepticus in adults\", section on 'Etiology'",
"    </a>",
"    .) The mechanism is unclear, and the infectious agent is generally not identified. Seizures are partial or secondarily generalized and are resistant to therapy, although some patients have responded to the ketogenic diet [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/42\">",
"     42",
"    </a>",
"    ]. Immunotherapies (immunoglobulin, corticosteroids, plasma exchange,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    ) are generally NOT helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/43\">",
"     43",
"    </a>",
"    ]. Mortality and morbidity (impaired cognition, refractory epilepsy) are high. In one series, seven patients who survived with chronic epilepsy had very similar seizures that were characterized by stereotypical perirolandic and perisylvian features (head and eye deviation, unilateral face and limb jerking, and asymmetric tonic posturing) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SYSTEMIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic changes frequently accompany prolonged seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/13\">",
"     13",
"    </a>",
"    ]. These complications contribute to the morbidity of SE and can be life-threatening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypoxemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxemia is thought to account for some of the complications of SE. It can result from impaired ventilation, increased oxygen consumption, or excessive salivation or tracheobronchial secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/13\">",
"     13",
"    </a>",
"    ]. Seizures associated with hypoxemia lead to further metabolic disturbances, including reduced brain glucose levels, lactic acidosis, and depletion of brain ATP. Severe hypoxemia and acidosis can result in impaired myocardial function, reduced cardiac output, and hypotension, further disrupting cellular function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactic acidosis and respiratory acidosis frequently accompany SE, resulting in one study in pH less than 7.0 in 13 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Glucose alterations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood glucose concentration typically is elevated at the start of seizures because of catecholamine release and sympathetic discharge. However, prolonged seizures often result in hypoglycemia as the metabolic demands outstrip the supply.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Blood pressure disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood pressure, heart rate, and central venous pressure rise at the start of SE as a result of massive release of catecholamine and sympathetic discharge. This rise is accompanied by a large increase in cerebral blood flow (200 to 700 percent in primates) thought to compensate for the brain's increased metabolic needs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/45\">",
"     45",
"    </a>",
"    ]. However, the blood pressure declines as the seizure persists, often resulting in hypotension. Cerebral blood flow also falls. Although it remains above normal levels, cerebral blood flow is inadequate to meet the increased demands for substrate and oxygen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Increased intracranial pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial pressure is increased during SE. This increase can further interfere with supply of substrate and oxygen and result in cerebral edema. Factors that contribute to increased intracranial pressure include metabolic acidosis, hypoxemia, and carbon dioxide retention with compensatory cerebral vasodilatation and increased cerebral blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated peripheral white blood cell count occurred in 60 percent of children in one series, although some patients had febrile illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/44\">",
"     44",
"    </a>",
"    ]. This increase probably is attributable to demargination of white cells associated with stress. In the same report, 13 percent had cerebrospinal fluid pleocytosis not caused by meningitis or encephalitis.",
"   </p>",
"   <p>",
"    Generalized muscle contractions can lead to elevated body temperature, and rhabdomyolysis can cause hyperkalemia, increased release of muscle enzymes, and myoglobinuria. Myoglobinuria associated with hypotension can result in acute renal failure.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=see_link\">",
"     \"Prevention and management of acute kidney injury (acute renal failure) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;SE can be fatal or associated with long-term morbidity, including seizure recurrence and neurologic problems. The outcome depends upon the underlying cause, the duration of the seizure, and age of the child [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality can result from the underlying condition or from respiratory, cardiovascular, or metabolic complications of SE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/47\">",
"     47",
"    </a>",
"    ]. The reported mortality rates of SE in children varies between 3 and 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/28,48-51\">",
"     28,48-51",
"    </a>",
"    ]. The underlying etiology is the main predictor of mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic sequelae of SE include focal motor deficits, mental retardation, behavioral disorders, and chronic epilepsy. One systematic review found that morbidity other than epilepsy occurred in 15 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/49\">",
"     49",
"    </a>",
"    ]. Neurologic sequelae are usually caused by the underlying condition rather than the seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/48,49,51\">",
"     48,49,51",
"    </a>",
"    ]. While some have noted that rates of neurologic sequelae are increased in younger patients with a longer duration of seizures, these factors are also linked to and difficult to separate from the underlying cause. Patients with cryptogenic SE and those with febrile SE do not have an increased incidence of recurrent seizures or other neurologic sequelae over baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/49,52\">",
"     49,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Recurrent seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for having future seizures of any type is high when SE is the child's first seizure, up to 50 percent in two reports [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/31,53\">",
"     31,53",
"    </a>",
"    ]. Recurrent SE also was more likely to occur in children who presented with SE (21 versus 1 percent in those with a brief initial seizure) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/31\">",
"     31",
"    </a>",
"    ]. Other risk factors for recurrence include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Remote symptomatic etiology",
"     </li>",
"     <li>",
"      Abnormal electroencephalogram",
"     </li>",
"     <li>",
"      Seizure during sleep",
"     </li>",
"     <li>",
"      History of prior febrile seizures",
"     </li>",
"     <li>",
"      Focal post-ictal deficits, including Todd's paresis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In other series, subsequent seizures occurred in 30 percent of 125 children with no history of prior unprovoked seizures, in spite of anticonvulsant treatment in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/48,54\">",
"     48,54",
"    </a>",
"    ]. Recurrent SE occurred in 16 to 17 percent in the first year of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/28,54\">",
"     28,54",
"    </a>",
"    ]. Recurrent SE occurred primarily in neurologically abnormal children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/28,54\">",
"     28,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Neurologic sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some children, especially those with prolonged",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inadequately treated SE, have residual neurologic sequelae, although rates are variable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/47,50,53,55,56\">",
"     47,50,53,55,56",
"    </a>",
"    ]. As with recurrence of seizure, neurologic outcome depends primarily on the underlying condition [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/51,57\">",
"     51,57",
"    </a>",
"    ]. In one review, encephalopathy and neurologic deficits occurred in 6 to 15 and 9 to 11 percent, respectively, of children and adults with SE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Refractory status epilepticus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory SE, which is defined as persistent seizure activity despite appropriate therapy, is associated with high mortality and morbidity. Two retrospective reviews have reported mortality of 17 and 32 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18888/abstract/47,58\">",
"     47,58",
"    </a>",
"    ]. Younger patients (&lt;5 years) and those with multifocal or generalized abnormalities on EEG were more likely to die. In survivors, recurrent seizures were common (31 to 97 percent) as were new neurologic deficits (71 to 100 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28752711\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The definition of status epilepticus (SE) is a seizure that lasts for 30 minutes or longer or is repeated frequently without regaining consciousness between seizures. However, for the purpose of treatment decisions, a shorter time definition (5 to 10 minutes) should be used as treatment delay is associated with delayed treatment response. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The usual classification of SE is similar to that for individual seizures and includes simple partial (continuous or repeated focal motor or sensory seizures without impaired consciousness), complex partial (continuous or repeated episodes of focal motor, sensory, or cognitive symptoms with impaired consciousness), generalized convulsive including tonic-clonic, tonic, and clonic (these are always associated with loss of consciousness), and generalized nonconvulsive including absence (petit mal) (characterized by altered awareness, but not necessarily unconsciousness). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SE can be a complication of acute illness such as encephalitis, or can occur as a manifestation of epilepsy. Between 10 and 20 percent of children with epilepsy will have at least one episode of SE. SE occurs as the first seizure in 12 percent of children with epilepsy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Epidemiology and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main contributor to the morbidity and mortality of SE is the underlying etiology. Systemic complications of SE also contribute to its associated morbidity and mortality; these include hypoxemia, acidemia, glucose alterations, and vascular changes. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Outcome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Systemic complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epilepsy is a frequent complication in a patient who presents with SE and may be as high as 20 percent. The presence of an underlying etiology causing neurologic abnormality increases the risk of epilepsy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Recurrent seizures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/1\">",
"      Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981; 22:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/2\">",
"      Berg AT, Shinnar S, Levy SR, Testa FM. Status epilepticus in children with newly diagnosed epilepsy. Ann Neurol 1999; 45:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/3\">",
"      Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med 1998; 338:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/4\">",
"      Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999; 40:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/5\">",
"      Shinnar S, Berg AT, Moshe SL, Shinnar R. How long do new-onset seizures in children last? Ann Neurol 2001; 49:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/6\">",
"      Eriksson K, Mets&auml;ranta P, Huhtala H, et al. Treatment delay and the risk of prolonged status epilepticus. Neurology 2005; 65:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/7\">",
"      Chin RF, Neville BG, Peckham C, et al. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol 2008; 7:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/8\">",
"      DeLorenzo RJ, Garnett LK, Towne AR, et al. Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes. Epilepsia 1999; 40:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/9\">",
"      Tay SK, Hirsch LJ, Leary L, et al. Nonconvulsive status epilepticus in children: clinical and EEG characteristics. Epilepsia 2006; 47:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/10\">",
"      Treiman DM. Electroclinical features of status epilepticus. J Clin Neurophysiol 1995; 12:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/11\">",
"      Abend NS, Dlugos DJ. Nonconvulsive status epilepticus in a pediatric intensive care unit. Pediatr Neurol 2007; 37:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/12\">",
"      Nei M, Lee JM, Shanker VL, Sperling MR. The EEG and prognosis in status epilepticus. Epilepsia 1999; 40:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/13\">",
"      Hanhan UA, Fiallos MR, Orlowski JP. Status epilepticus. Pediatr Clin North Am 2001; 48:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/14\">",
"      Teitelbaum JS, Zatorre RJ, Carpenter S, et al. Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med 1990; 322:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/15\">",
"      Wasterlain CG, Fujikawa DG, Penix L, Sankar R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993; 34 Suppl 1:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/16\">",
"      Wasterlain CG, Baxter CF, Baldwin RA. GABA metabolism in the substantia nigra, cortex, and hippocampus during status epilepticus. Neurochem Res 1993; 18:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/17\">",
"      Coulter DA. Chronic epileptogenic cellular alterations in the limbic system after status epilepticus. Epilepsia 1999; 40 Suppl 1:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/18\">",
"      Macdonald RL, Kapur J. Acute cellular alterations in the hippocampus after status epilepticus. Epilepsia 1999; 40 Suppl 1:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/19\">",
"      Fazekas F, Kapeller P, Schmidt R, et al. Magnetic resonance imaging and spectroscopy findings after focal status epilepticus. Epilepsia 1995; 36:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/20\">",
"      Lansberg MG, O'Brien MW, Norbash AM, et al. MRI abnormalities associated with partial status epilepticus. Neurology 1999; 52:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/21\">",
"      Inoue S. [A clinical study on neuron-specific enolase activities in cerebrospinal fluid of neonates]. No To Hattatsu 1992; 24:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/22\">",
"      DeGiorgio CM, Gott PS, Rabinowicz AL, et al. Neuron-specific enolase, a marker of acute neuronal injury, is increased in complex partial status epilepticus. Epilepsia 1996; 37:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/23\">",
"      Correale J, Rabinowicz AL, Heck CN, et al. Status epilepticus increases CSF levels of neuron-specific enolase and alters the blood-brain barrier. Neurology 1998; 50:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/24\">",
"      DeGiorgio CM, Heck CN, Rabinowicz AL, et al. Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology 1999; 52:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/25\">",
"      Doose H, V&ouml;lzke E. Petit mal status in early childhood and dementia. Neuropadiatrie 1979; 10:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/26\">",
"      Pakalnis A, Paolicchi J, Gilles E. Psychogenic status epilepticus in children: psychiatric and other risk factors. Neurology 2000; 54:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/27\">",
"      Shinnar S, Pellock JM, Mosh&eacute; SL, et al. In whom does status epilepticus occur: age-related differences in children. Epilepsia 1997; 38:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/28\">",
"      Chin RF, Neville BG, Peckham C, et al. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet 2006; 368:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/29\">",
"      Raspall-Chaure M, Chin RF, Neville BG, et al. The epidemiology of convulsive status epilepticus in children: a critical review. Epilepsia 2007; 48:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/30\">",
"      Singh RK, Stephens S, Berl MM, et al. Prospective study of new-onset seizures presenting as status epilepticus in childhood. Neurology 2010; 74:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/31\">",
"      Shinnar S, Berg AT, Moshe SL, et al. The risk of seizure recurrence after a first unprovoked afebrile seizure in childhood: an extended follow-up. Pediatrics 1996; 98:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/32\">",
"      Haut SR, Shinnar S, Mosh&eacute; SL, et al. The association between seizure clustering and convulsive status epilepticus in patients with intractable complex partial seizures. Epilepsia 1999; 40:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/33\">",
"      Novak G, Maytal J, Alshansky A, Ascher C. Risk factors for status epilepticus in children with symptomatic epilepsy. Neurology 1997; 49:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/34\">",
"      Berg AT, Shinnar S, Testa FM, et al. Status epilepticus after the initial diagnosis of epilepsy in children. Neurology 2004; 63:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/35\">",
"      Ferraro TN, Golden GT, Smith GG, Berrettini WH. Differential susceptibility to seizures induced by systemic kainic acid treatment in mature DBA/2J and C57BL/6J mice. Epilepsia 1995; 36:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/36\">",
"      Schauwecker PE, Steward O. Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc Natl Acad Sci U S A 1997; 94:4103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/37\">",
"      Corey LA, Pellock JM, Boggs JG, et al. Evidence for a genetic predisposition for status epilepticus. Neurology 1998; 50:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/38\">",
"      Watemberg N, Segal G. A suggested approach to the etiologic evaluation of status epilepticus in children: what to seek after the usual causes have been ruled out. J Child Neurol 2010; 25:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/39\">",
"      Kramer U, Chi CS, Lin KL, et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia 2011; 52:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/40\">",
"      van Baalen A, H&auml;usler M, Boor R, et al. Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood. Epilepsia 2010; 51:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/41\">",
"      Ismail FY, Kossoff EH. AERRPS, DESC, NORSE, FIRES: multi-labeling or distinct epileptic entities? Epilepsia 2011; 52:e185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/42\">",
"      Nabbout R, Mazzuca M, Hubert P, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia 2010; 51:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/43\">",
"      Howell KB, Katanyuwong K, Mackay MT, et al. Long-term follow-up of febrile infection-related epilepsy syndrome. Epilepsia 2012; 53:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/44\">",
"      Dunn DW. Status epilepticus in children: etiology, clinical features, and outcome. J Child Neurol 1988; 3:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/45\">",
"      Meldrum BS, Brierley JB. Prolonged epileptic seizures in primates. Ischemic cell change and its relation to ictal physiological events. Arch Neurol 1973; 28:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/46\">",
"      Gabor AJ, Brooks AG, Scobey RP, Parsons GH. Intracranial pressure during epileptic seizures. Electroencephalogr Clin Neurophysiol 1984; 57:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/47\">",
"      Lambrechtsen FA, Buchhalter JR. Aborted and refractory status epilepticus in children: a comparative analysis. Epilepsia 2008; 49:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/48\">",
"      Maytal J, Shinnar S, Mosh&eacute; SL, Alvarez LA. Low morbidity and mortality of status epilepticus in children. Pediatrics 1989; 83:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/49\">",
"      Raspall-Chaure M, Chin RF, Neville BG, Scott RC. Outcome of paediatric convulsive status epilepticus: a systematic review. Lancet Neurol 2006; 5:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/50\">",
"      Novorol CL, Chin RF, Scott RC. Outcome of convulsive status epilepticus: a review. Arch Dis Child 2007; 92:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/51\">",
"      Kravljanac R, Jovic N, Djuric M, et al. Outcome of status epilepticus in children treated in the intensive care unit: a study of 302 cases. Epilepsia 2011; 52:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/52\">",
"      Shinnar S, Pellock JM, Berg AT, et al. Short-term outcomes of children with febrile status epilepticus. Epilepsia 2001; 42:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/53\">",
"      Barnard C, Wirrell E. Does status epilepticus in children cause developmental deterioration and exacerbation of epilepsy? J Child Neurol 1999; 14:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/54\">",
"      Shinnar S, Maytal J, Krasnoff L, Moshe SL. Recurrent status epilepticus in children. Ann Neurol 1992; 31:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/55\">",
"      Fountain NB. Status epilepticus: risk factors and complications. Epilepsia 2000; 41 Suppl 2:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/56\">",
"      Verity CM, Ross EM, Golding J. Outcome of childhood status epilepticus and lengthy febrile convulsions: findings of national cohort study. BMJ 1993; 307:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/57\">",
"      Verity CM. Do seizures damage the brain? The epidemiological evidence. Arch Dis Child 1998; 78:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18888/abstract/58\">",
"      Sahin M, Menache CC, Holmes GL, Riviello JJ. Outcome of severe refractory status epilepticus in children. Epilepsia 2001; 42:1461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6222 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18888=[""].join("\n");
var outline_f18_28_18888=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28752711\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Electrical (subclinical) seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neuronal loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - MR imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Neuron-specific enolase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EPIDEMIOLOGY AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SYSTEMIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Glucose alterations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Blood pressure disturbances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Increased intracranial pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Morbidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Recurrent seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Neurologic sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Refractory status epilepticus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28752711\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=related_link\">",
"      Nonepileptic paroxysmal disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=related_link\">",
"      Prevention and management of acute kidney injury (acute renal failure) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_28_18889="Renal hypoplasia";
var content_f18_28_18889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal hypoplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) High power light microscopy shows large glomeruli with interstitial fibrosis and foci of atrophic tubules in a patient with renal hypoplasia and chronic renal disease. B) High power light microscopy of normal kidney.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Patrick Niaudet.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18889=[""].join("\n");
var outline_f18_28_18889=null;
var title_f18_28_18890="Diagnosis and clinical manifestations of essential thrombocythemia";
var content_f18_28_18890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and clinical manifestations of essential thrombocythemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/28/18890/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18890/contributors\">",
"     Ayalew Tefferi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/28/18890/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18890/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/28/18890/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/28/18890/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/28/18890/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic myeloproliferative disorders (CMPD) are classified into several subgroups, of which four are well characterized (",
"    <a class=\"graphic graphic_figure graphicRef56283 \" href=\"UTD.htm?24/16/24835\">",
"     figure 1",
"    </a>",
"    ): chronic myeloid leukemia (CML), polycythemia vera (PV), primary myelofibrosis (PMF), and essential thrombocythemia (ET, also called essential thrombocytosis or primary thrombocytosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CML, PV, and PMF can be diagnosed via well accepted clinical and laboratory criteria; ET is alone among these CMPDs in that it is diagnosed by excluding causes of reactive thrombocytosis, and by excluding presence of the other CMPDs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/2\">",
"     2",
"    </a>",
"    ]. At present, ET is not a cytogenetically or morphologically defined disease entity; the diagnosis of ET refers to the presence of a chronic",
"    <strong>",
"     nonreactive",
"    </strong>",
"    thrombocythemic state that is not accounted for by one of the other chronic myeloproliferative disorders (CMPDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of ET will be reviewed here. The general approach to the patient with an elevated platelet count, and the treatment of ET are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=see_link\">",
"     \"Approach to the patient with thrombocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=see_link\">",
"     \"Prognosis and treatment of essential thrombocythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither thrombopoietin (TPO) nor its receptor (c-Mpl) has been implicated in the pathogenesis of ET. Mutations involving the c-Mpl gene are only rarely identified in ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/4\">",
"     4",
"    </a>",
"    ], and endogenous megakaryocyte colony growth does not appear to be dependent on an autocrine stimulation involving TPO [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This is in contrast to autosomal dominant familial essential thrombocythemia where activating mutations in the genes for TPO or c-Mpl, or mutations in the genes for other proteins are responsible for TPO-mediated thrombocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=see_link&amp;anchor=H11#H11\">",
"     \"Biology and physiology of thrombopoietin\", section on 'Familial thrombocythemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum TPO levels in ET have been reported to be inappropriately normal or elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This unexpected finding may be a result of increased bone marrow stromal production of TPO [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/9\">",
"     9",
"    </a>",
"    ] or decreased ligand clearance associated with reduced platelet c-Mpl expression in patients with ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clonality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of glucose-6-phosphate dehydrogenase enzyme-based clonal assays suggested that ET, as well as polycythemia vera, represented a clonal stem cell disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent investigations, which used X-linked DNA and transcript analysis, demonstrated a variable pattern of lineage involvement that suggested hierarchically different levels of clonal generation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/7,13,14\">",
"     7,13,14",
"    </a>",
"    ]. The issue of clonality in ET is further confounded by the complexity of X-linked clonality testing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/15\">",
"     15",
"    </a>",
"    ], which has resulted in the demonstration of monoclonal hematopoiesis in normal elderly females [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/16\">",
"     16",
"    </a>",
"    ] and polyclonal hematopoiesis in up to 50 percent of patients with ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/3,17-19\">",
"     3,17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Population-based epidemiologic studies in Rochester, Minnesota have suggested an incidence rate for ET of 2.5 new",
"    <span class=\"nowrap\">",
"     cases/100,000",
"    </span>",
"    population per year [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/20\">",
"     20",
"    </a>",
"    ]. In the United States, approximately 6000 people are diagnosed each year as having ET. Because life expectancy appears to be normal in ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], the prevalence of the disease is much higher, and has been estimated at 24 total",
"    <span class=\"nowrap\">",
"     cases/100,000",
"    </span>",
"    population [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have reported a female preponderance in ET (female to male ratio of approximately 2:1) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. The median age at diagnosis is 60 years and as many as 20 percent of the patients may be younger than 40 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/27\">",
"     27",
"    </a>",
"    ]. Five- and 10-year survivals of 74 to 93 and 61 to 84 percent, respectively, have been noted in ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/25,28,29\">",
"     25,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Childhood ET",
"    </span>",
"    &nbsp;&mdash;&nbsp;ET is extremely rare in children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/30-35\">",
"     30-35",
"    </a>",
"    ]. Population-based studies in Denmark and British Columbia have estimated an annual incidence of ET of 0.09 per million in children up to 14 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When ET does occur in children, it appears to be relatively benign. This was shown in a study of 64 consecutive patients &lt;20 years of age being evaluated for a Philadelphia chromosome-negative myeloproliferative neoplasm. Of these, 34 were found to have sporadic thrombocythemia (ST) and 16 hereditary thrombocytosis (HT) by use of either the PVSG or WHO criteria. Observations included [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 50 subjects with either ST or HT, there were no prior episodes or thrombosis or bleeding. Symptoms were present in 16, and consisted of headaches in 13 and paresthesias in three. Splenomegaly was present in eight.",
"     </li>",
"     <li>",
"      In the group with ST, 47.5 percent carried the JAK2V617F mutation, while none had a MPL mutation. In the group with HT, none had the JAK2 mutation and 15 had a MPL mutation.",
"     </li>",
"     <li>",
"      After a median follow-up of 128 months for ST and 137 months for HT, no patient had developed acute leukemia or post-ET myelofibrosis, while three patients experienced a non-fatal thrombotic episode.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In two small studies, the percent of female children with a monoclonal pattern was 27 and 73 percent, while positivity for the JAK2 mutation was seen in 20 and 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to one-half of patients with ET may be totally asymptomatic at presentation. The remaining patients may report \"vasomotor\" symptoms or manifest thrombohemorrhagic complications. However, there exists a wide range in the reported incidence rates of disease-related complications in ET because of inter-study differences in patient selection and the definition of what constitutes a \"vasomotor symptom\", \"hemorrhage\", or \"thrombotic event\". Unlike the situation in the related disorder polycythemia vera, pruritus is very uncommon in ET, occurring in less than 5 percent of our series of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vasomotor symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a series of 74 young women with ET seen at our institution, the incidence of \"vasomotor symptoms\" was 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/22\">",
"     22",
"    </a>",
"    ]. The incidence in a previous report of an unselected group of 147 patients was 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/25,39\">",
"     25,39",
"    </a>",
"    ]. Vasomotor manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Lightheadedness",
"     </li>",
"     <li>",
"      Syncope",
"     </li>",
"     <li>",
"      Atypical chest pain",
"     </li>",
"     <li>",
"      Acral paresthesia",
"     </li>",
"     <li>",
"      Livedo reticularis",
"     </li>",
"     <li>",
"      Erythromelalgia (burning pain of the hands or feet associated with erythema and warmth) (",
"      <a class=\"graphic graphic_picture graphicRef81121 \" href=\"UTD.htm?17/25/17808\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transient visual disturbances (eg, amaurosis fugax, scintillating scotomata, ophthalmic migraine) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies have correlated thromboxane-dependent platelet activation and subsequent arterial microvascular thrombosis with erythromelalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. These events are generally more bothersome than dangerous, and are usually controlled by treatment with low or standard doses of acetylsalicylic acid (ASA) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/44\">",
"     44",
"    </a>",
"    ]. However, vasomotor symptoms in some patients may be resistant to antiplatelet therapy and may require the institution of cytoreductive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=see_link&amp;anchor=H19#H19\">",
"     \"Prognosis and treatment of essential thrombocythemia\", section on 'Low dose aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Thrombosis and hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis and hemorrhage are common complications of ET, likely due to qualitative and quantitative platelet alterations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/19,46\">",
"     19,46",
"    </a>",
"    ]. In our series of 74 young women with ET, the respective incidences of thrombosis and hemorrhage, at diagnosis, were 18 percent and 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the corresponding figures for \"major\" thrombotic or hemorrhagic events were 7 percent and 4 percent. Other studies have reported incidence rates of thrombosis and hemorrhage at diagnosis ranging from 9 to 22 percent and 3 to 37 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/24-27,39,47\">",
"     24-27,39,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After diagnosis, reported rates for subsequent thrombosis and hemorrhage, over a median follow-up duration of three to seven years, range from 7 to 17 percent and 8 to 14 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/24-26,39,47\">",
"     24-26,39,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median follow-up period in our group of young women with ET was &gt;9 years (range: 0.2 to 26 years); during this time, 18 and 4 percent of the patients developed thrombotic (exclusive of superficial thrombosis) and major hemorrhagic complications, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a larger series of 891 patients with WHO-defined ET, after a median follow-up of 6.2 years, the rate of fatal or nonfatal thrombotic events was 1.9 per 100 patient years [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Predictors of arterial thrombosis in this group included age &gt;60, history of thrombosis, presence of cardiovascular risk factors (eg, tobacco use, hypertension, diabetes mellitus), white blood cell count",
"      <span class=\"nowrap\">",
"       &gt;11,000/microL,",
"      </span>",
"      and presence of the JAK2 V617F mutation.",
"     </li>",
"     <li>",
"      Of interest, the presence of a platelet count &gt;1000 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        6",
"       </sup>",
"       /microL",
"      </span>",
"      was associated with a significantly decreased risk for arterial thrombosis (HR 0.42; 95% CI 0.22-0.78), presumably because of the occurrence of acquired von Willebrand disease in this group of patients (see below). However, there was no correlation between extreme thrombocytosis and major bleeding in this study.",
"     </li>",
"     <li>",
"      Only male gender predicted for venous thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thrombotic events in ET have included stroke, transient ischemic attacks, retinal artery or venous occlusions, coronary artery ischemia, pulmonary embolism, hepatic or portal vein thrombosis, deep vein thrombosis, and digital ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/29\">",
"     29",
"    </a>",
"    ]. Digital ischemia may start as the Raynaud phenomenon with pallor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyanosis of the digits and dysesthesia, and may progress to ischemic necrosis of the terminal phalanges.",
"   </p>",
"   <p>",
"    In our series of 305 female patients with ET, the use of estrogen-containing hormone therapy was not associated with an increase in venous or arterial thrombotic events [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/49\">",
"     49",
"    </a>",
"    ]. However, the use of oral contraceptives was associated with a 3-fold increased risk of venous thrombosis (23 versus 7 percent) and a 5-fold increased risk of splanchnic thrombosis (15 versus 3 percent).",
"   </p>",
"   <p>",
"    Bleeding manifestations at initial presentation of ET are relatively frequent; the risk is significantly associated with extreme thrombocytosis (platelet count &gt;1",
"    <span class=\"nowrap\">",
"     million/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/26\">",
"     26",
"    </a>",
"    ], &gt;1.5",
"    <span class=\"nowrap\">",
"     million/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/22\">",
"     22",
"    </a>",
"    ], and &gt;2",
"    <span class=\"nowrap\">",
"     million/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/25\">",
"     25",
"    </a>",
"    ]), the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in doses &gt;325",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    or following treatment with nonsteroidal antiinflammatory drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/24,27,47,50\">",
"     24,27,47,50",
"    </a>",
"    ]. However, the risk of major bleeding, as well as thrombosis may be high post-surgery even in patients with well-controlled disease, or who are receiving thromboprophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients with ET or PV and platelet counts &gt;1",
"    <span class=\"nowrap\">",
"     million/microL,",
"    </span>",
"    acquired von Willebrand disease may be present. Such patients may have increased bleeding, especially when treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . Cytoreduction usually corrects both the clinical and laboratory abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/46,52-55\">",
"     46,52-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H13#H13\">",
"     \"Classification and pathophysiology of von Willebrand disease\", section on 'Acquired von Willebrand disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Disease transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the previously cited group of 74 young females with ET, transformation into PV, PMF, or acute myeloid leukemia (AML) occurred in 2.7, 4 , and 1.4 percent of the patients, respectively, after a median follow-up period of 9.2 years (range: 0.2 to 26 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/22\">",
"     22",
"    </a>",
"    ]. The single patient in our series who developed AML 12 years after diagnosis had been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    for that entire period of time (",
"    <a class=\"graphic graphic_table graphicRef54519 \" href=\"UTD.htm?5/55/6013\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The transformation of ET into myelofibrosis with myeloid metaplasia (MMM) or PV has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/56-60\">",
"     56-60",
"    </a>",
"    ], with incidences generally similar to our own experience. It is not clear whether specific therapy for ET modifies the risk of fibrotic transformation, or whether the prognosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment of post-thrombocythemic MMM differ from that of patients with de novo MMM [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previous retrospective studies with median follow-up durations of three to seven years have reported incidence figures of leukemic conversion ranging from 0.6 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/25,26,39,47,61\">",
"     25,26,39,47,61",
"    </a>",
"    ]. Elapsed time to leukemic conversion in most studies has ranged from 1.7 to 16 years. The reported FAB subtypes of resulting AML have included M1, M2, M4, and M7, the latter being of megakaryoblastic origin (ie, acute megakaryoblastic leukemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39720?source=see_link\">",
"     \"Classification of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most transformed patients were previously treated with cytoreductive therapy; of importance, most patients who developed AML after ET received more than one agent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/56,62\">",
"     56,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=see_link&amp;anchor=H10#H10\">",
"     \"Prognosis and treatment of essential thrombocythemia\", section on 'Hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, leukemic conversions in ET have also occurred in the absence of previous therapy, suggesting that the event may be a natural sequela of the disease that depends more on disease biology and duration than specific therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. In support of this is the case of a young woman who had ET for 18 years before she transformed into AML with complex cytogenetic abnormalities. This patient had received no previous therapy and had an unremarkable marrow morphology and normal cytogenetics at the time of initial diagnosis of ET.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have previously published our experience with 34 pregnancies occurring in 18 patients with ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/65\">",
"     65",
"    </a>",
"    ]. In that study, 45 percent of the pregnancies ended in spontaneous abortions, primarily occurring in the first trimester. The occurrence of abortions could not be predicted from the disease course, platelet count, or specific therapy.",
"   </p>",
"   <p>",
"    For those pregnancies carried to term, complications during delivery were infrequent, even in the absence of prophylactic platelet apheresis. The outcome of pregnancy was not different between patients who received no specific therapy and those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone. Three pregnancies were carried to term, and resulted in deliveries of healthy babies, despite the use of radioactive 32P or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    around the time of conception.",
"   </p>",
"   <p>",
"    A decrease in platelet count in patients with ET during pregnancy is well documented; in our updated series of 43 pregnancies, the platelet count dropped from a median of 1.1",
"    <span class=\"nowrap\">",
"     million/microL",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     600,000/microL.",
"    </span>",
"    In a separate study, this fall in platelet count was independent of the presence or absence of the V617F JAK2 mutation, although this mutation was an independent risk factor for the development of pregnancy complications (OR 2.0; 95% CI 1.1-3.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of the literature, the miscarriage rate in 106 pregnancies in 57 women with ET was 43 percent, 36 percent of which occurred in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/67\">",
"     67",
"    </a>",
"    ]. Similar rates were noted in an Italian study of 103 pregnancies in 62 women with ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/66\">",
"     66",
"    </a>",
"    ]. Other complications included stillbirth (5 percent), premature delivery (8 percent), preeclampsia (4 percent), and fetal growth retardation (4 percent). In this and another report, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy, was associated with a decreased incidence of miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/68\">",
"     68",
"    </a>",
"    ]. However, these reports suffer from event selection bias stemming from underreporting of uneventful outcomes as well as early spontaneous abortions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Physical examination and laboratory results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 25 to 48 percent of the patients present with palpable splenomegaly, usually only modest in degree [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/22,26,69\">",
"     22,26,69",
"    </a>",
"    ]. Hepatomegaly and lymphadenopathy are uncommon.",
"   </p>",
"   <p>",
"    Initial history, clinical, and laboratory characteristics of 150 patients with ET seen at our institution are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef65000 \" href=\"UTD.htm?39/18/40235\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary hypertension, often asymptomatic, has been detected in patients with ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. The clinical importance of this finding is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alone among the chronic myeloproliferative disorders (ie, ET, PV, PMF, and CML), ET is the only one which is currently diagnosed by exclusion. Thus, ET may be diagnosed in patients with persistent thrombocytosis only in the absence of a known cause of reactive or clonal thrombocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=see_link&amp;anchor=H24#H24\">",
"     \"Approach to the patient with thrombocytosis\", section on 'Essential thrombocythemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of criteria have been proposed for making the diagnosis of ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/56,74-78\">",
"     56,74-78",
"    </a>",
"    ]. Some of these are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnostic criteria of the PVSG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first large-scale attempt to diagnose ET in a prospective manner was taken by the Polycythemia Vera Study Group (PVSG). In order to qualify for this diagnosis, the patient had to fulfill all of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &gt;600,000/microL",
"      </span>",
"      <span class=\"nowrap\">",
"       (&gt;1,000,000/microL",
"      </span>",
"      for entering therapeutic protocols)",
"     </li>",
"     <li>",
"      Megakaryocytic hyperplasia on bone marrow aspiration and biopsy (",
"      <a class=\"graphic graphic_picture graphicRef67362 \" href=\"UTD.htm?24/34/25127\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Absence of the Philadelphia chromosome",
"     </li>",
"     <li>",
"      Absence of infection, inflammation, and other causes for reactive thrombocytosis",
"     </li>",
"     <li>",
"      Normal red blood cell (RBC) mass or a hemoglobin concentration &lt;13",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Presence of stainable iron in a bone marrow aspiration or &le;1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      increase in hemoglobin concentration after a one month trial of oral iron therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients were also excluded if there was collagen fibrosis involving more than one-third of the cross-sectional area of the bone marrow biopsy, or if there were lesser degrees of collagen fibrosis in the presence of splenomegaly and a leukoerythroblastic blood picture [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/74,79\">",
"     74,79",
"    </a>",
"    ]. These latter patients had a presumptive diagnosis of the cellular phase of PMF.",
"   </p>",
"   <p>",
"    After more than 20 years, these criteria are still considered to be the \"gold standard\" for the diagnosis of ET, although they have been \"modernized\", as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A consistently elevated platelet count",
"      <span class=\"nowrap\">",
"       &gt;450,000/microL",
"      </span>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef61742 \" href=\"UTD.htm?22/0/22536\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef68024 \" href=\"UTD.htm?20/49/21265\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Megakaryocytic hyperplasia on bone marrow aspiration and biopsy (",
"      <a class=\"graphic graphic_picture graphicRef67362 \" href=\"UTD.htm?24/34/25127\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Absence of the Philadelphia chromosome on routine cytogenetic study. Molecular studies of the",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      gene rearrangement are now recommended to exclude cytogenetically masked cases of CML [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Absence of causes for reactive thrombocytosis (",
"      <a class=\"graphic graphic_table graphicRef74148 \" href=\"UTD.htm?32/7/32892\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Absence of peripheral blood, bone marrow, and karyotypic evidence for a myelodysplastic (MDS) disorder or for PMF (see below)",
"     </li>",
"     <li>",
"      Normal iron stores, as evidenced by normal serum ferritin and normal red cell mean corpuscular volume (MCV). Red cell mass measurement is not necessary in the presence of a hematocrit &lt;40 percent, but is recommended in all other patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The World Health Organization criteria for the diagnosis of ET are similar to those presented above [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/75,76\">",
"     75,76",
"    </a>",
"    ], although revised WHO criteria have been published. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'WHO criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In general, a persistent and otherwise unexplained elevation in platelet count in a patient with an intact spleen, and normal serum ferritin and C-reactive protein levels suggests a diagnosis of ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=see_link&amp;anchor=H15#H15\">",
"     \"Approach to the patient with thrombocytosis\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     JAK2 mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our series of patients and that of others, approximately 50 percent of patients with ET have shown presence of the JAK2 V617F mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/19,82,83\">",
"     19,82,83",
"    </a>",
"    ]. Presence of this mutation enables one to differentiate patients with myeloproliferative neoplasm-associated thrombocytosis from those with reactive thrombocytosis. However, it does not allow differentiation among ET, PV, and PMF, nor does it differentiate between those patients with ET and clonal versus polyclonal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the myeloproliferative neoplasms\", section on 'Mutations in PV, ET, and PMF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between presence of the JAK2 mutation and the clinical and laboratory manifestations of ET is unclear at this time. although the following observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In our series, patients with ET and this mutation had higher total white blood cell counts and hemoglobin levels, lower platelet counts, and were more likely to transform into PV than those without this mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/70,86\">",
"       70,86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two other studies also found higher hemoglobin levels in patients with ET and the JAK2 mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/87,88\">",
"       87,88",
"      </a>",
"      ], while three studies found a higher incidence of thrombosis in those with the JAK2 mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/87,89,90\">",
"       87,89,90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third study of 82 patients with ET found higher total white blood cell counts and a higher incidence of thrombosis in those patients who demonstrated this mutation in both platelets and granulocytes as compared with those whose platelets and granulocytes were both negative for this mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a series of female patients with ET informative at the HUMARA locus, 67 percent demonstrated clonal granulopoiesis; the JAK2 mutation, as measured by real time PCR, was present in 72 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/84\">",
"     84",
"    </a>",
"    ]. Twenty-two percent of the patients with ET had clonal granulopoiesis by HUMARA and were JAK2 mutation negative. A similar subset (ie, clonal by HUMARA, JAK2 mutation negative) was also noted in patients with PMF (55 percent) but not in those with polycythemia vera (PV), suggesting that mutations other than JAK2 are necessary in ET and PMF, but not in PV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     MPL mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In three large studies, MPL mutations were found in 1 to 4 percent of patients with ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/4,91,92\">",
"     4,91,92",
"    </a>",
"    ]. MPL mutations lacked prognostic significance with respect to thrombosis, major hemorrhage, myelofibrotic transformation, or survival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other studies commonly performed in the CMPDs, which may or may not be helpful in this regard, include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=see_link&amp;anchor=H15#H15\">",
"     \"Approach to the patient with thrombocytosis\", section on 'Laboratory evaluation'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum TPO levels are often elevated in both ET and RT and may not be useful in distinguishing one from the other [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although endogenous in vitro megakaryocyte",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      erythroid colony formation may be seen in the majority of patients with ET and in none of those with RT, the particular assay requires considerable expertise and is not widely available [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A bone marrow examination with cytogenetic studies helps exclude the possibility of another chronic myeloid disorder mimicking ET [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/95-98\">",
"       95-98",
"      </a>",
"      ]. As an example, the presence of the Philadelphia (Ph1) chromosome",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the associated BCR-ABL gene rearrangement mandates the diagnosis of CML. The incidence of clonal cytogenetic abnormalities in ET is approximately 5 percent, although none is diagnostic of ET [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overexpression of the PRV-1 gene in peripheral blood granulocytes has been noted in both ET and polycythemia vera, but not in patients with secondary thrombocytosis or secondary erythrocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/100,101\">",
"       100,101",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sensitivity of progenitor cells to thrombopoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased sensitivity of circulating hematopoietic progenitor cells to thrombopoietin in vitro was found in 18 of 20 patients with ET, one of eight patients with secondary thrombocytosis, and zero of 22 healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/102\">",
"     102",
"    </a>",
"    ]. Similarly, endogenous megakaryocyte colony formation was found in 11 of 11 patients with ET and in none of 6 patients with RT or 7 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the sensitivity and specificity of these observations are confirmed, they may offer the basis for distinguishing ET from RT. However, endogenous megakaryocyte colony formation does not appear to distinguish ET (positive in 40 of 42 patients) from PV (positive in 47 of 50 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     WHO criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization criteria for making the diagnosis of ET are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef52174 \" href=\"UTD.htm?16/37/16988\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/77,105,106\">",
"     77,105,106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions which must be distinguished from ET include reactive thrombocytosis (RT), CML, PV, PMF, and MDS. They will be briefly described here, as more extensive discussion of their diagnosis can be found elsewhere in the program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Reactive thrombocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of medical and surgical conditions can result in reactive thrombocytosis (RT) (",
"    <a class=\"graphic graphic_table graphicRef74148 \" href=\"UTD.htm?32/7/32892\">",
"     table 3",
"    </a>",
"    ). These include iron deficiency anemia, surgical or functional asplenia, metastatic cancer, trauma (surgical or otherwise), acute bleeding or hemolysis, and a variety of infectious or inflammatory processes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/2,107,108\">",
"     2,107,108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the patient with thrombocytosis\", section on 'Other testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a cause for RT is not readily apparent, the demonstration of elevated acute-phase reactants (C-reactive protein [CRP], fibrinogen, erythrocyte sedimentation rate, ferritin) may be used as evidence for the presence of an occult inflammatory process [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/81,109-111\">",
"     81,109-111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Chronic myeloid leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Demonstration of the",
"    <span class=\"nowrap\">",
"     BCR/ABL",
"    </span>",
"    translocation between chromosomes 9 and 22 mandates a diagnosis of chronic myeloid leukemia (CML) (",
"    <a class=\"graphic graphic_figure graphicRef62227 \" href=\"UTD.htm?16/20/16719\">",
"     figure 2",
"    </a>",
"    ). This is particularly relevant to patients with CML who may present with either isolated thrombocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/98,112,113\">",
"     98,112,113",
"    </a>",
"    ] or substantial bone marrow fibrosis, and who otherwise might have been diagnosed as having ET or PMF, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Other myeloproliferative neoplasms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Polycythemia vera",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clonal JAK2 mutation-positive chronic myeloproliferative disorder associated with an increased red cell mass (RCM) defines polycythemia vera (PV). A number of diagnostic criteria and algorithms are available for making this diagnosis (",
"    <a class=\"graphic graphic_table graphicRef77810 \" href=\"UTD.htm?40/43/41659\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link&amp;anchor=H28#H28\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\", section on 'Establishing the diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Primary myelofibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of bone marrow reticulin fibrosis along with a leukoerythroblastic blood picture (",
"    <a class=\"graphic graphic_picture graphicRef68110 \" href=\"UTD.htm?29/43/30390\">",
"     picture 5",
"    </a>",
"    ) is a prerequisite for the diagnosis of primary myelofibrosis (PMF). Various sets of criteria are available for making this diagnosis (",
"    <a class=\"graphic graphic_table graphicRef51995 \" href=\"UTD.htm?24/59/25531\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66012 \" href=\"UTD.htm?26/8/26764\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, bone marrow findings in essential thrombocythemia show significant overlap with those seen in patients with prefibrotic myelofibrosis, such that this distinction may not be easily made [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/77,115,116\">",
"     77,115,116",
"    </a>",
"    ]. The differentiation between PMF and ET is dependent primarily on the presence of megakaryocyte proliferation and atypia, degree of bone marrow fibrosis and splenomegaly, and the presence of peripheral blood leukoerythroblastosis in PMF (",
"    <a class=\"graphic graphic_table graphicRef52174 \" href=\"UTD.htm?16/37/16988\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66012 \" href=\"UTD.htm?26/8/26764\">",
"     table 7",
"    </a>",
"    ). Distinguishing between these two conditions is important because of major differences in survival and complication rates between them [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/116,117\">",
"     116,117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Myelodysplastic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myelodysplastic syndromes are a series of related diseases with varying degrees of disordered hematopoietic maturation (",
"    <a class=\"graphic graphic_table graphicRef51895 \" href=\"UTD.htm?20/33/21020\">",
"     table 8",
"    </a>",
"    ). Although most are associated with thrombocytopenia, a few, such as the 5q- syndrome, are associated with thrombocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/97,118,119\">",
"     97,118,119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H37#H37\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14905?source=see_link&amp;anchor=H256821606#H256821606\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\", section on '5q- syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Familial essential thrombocythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial essential thrombocythemia, also called hereditary or inherited thrombocythemia or thrombocytosis, is a rare disorder transmitted in an autosomal dominant pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/120-126\">",
"     120-126",
"    </a>",
"    ]. Analysis of affected members of one family revealed a single point mutation in the splice donor site of intron 3 of the thrombopoietin gene [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/121\">",
"     121",
"    </a>",
"    ]. The mutant gene produced a new thrombopoietin mRNA with a normal protein coding region but with a shortened 5' untranslated region that was more efficiently translated than normal thrombopoietin transcripts. The net effect is more thrombopoietin protein synthesis, higher plasma thrombopoietin concentrations, and chronically elevated platelet counts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=see_link\">",
"     \"Biology and physiology of thrombopoietin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar mutation has been described in several other families [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/122\">",
"     122",
"    </a>",
"    ]. However, familial essential thrombocythemia is a heterogeneous disorder as families have been described with an activating mutation in the gene for the TPO receptor (c-MPL), the thrombopoietin gene, a germline mutation in JAK2 V617I [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/123,127-129\">",
"     123,127-129",
"    </a>",
"    ], or without a mutation in any of these genes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/124,130\">",
"     124,130",
"    </a>",
"    ]. Mutations in the TPO or c-MPL gene do not appear to be commonly involved in sporadic cases of ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Suspecting the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of essential thrombocythemia (ET), a member of the family of chronic myeloproliferative disorders (MPDs), is suspected in a patient with a chronically elevated platelet count, often, but not always, accompanied by clinical thrombotic or hemorrhagic symptoms and the presence of a mild degree of splenomegaly (",
"    <a class=\"graphic graphic_table graphicRef65000 \" href=\"UTD.htm?39/18/40235\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Making the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ET is made by exclusion. Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Causes of reactive thrombocytosis must be ruled out (",
"      <a class=\"graphic graphic_table graphicRef74148 \" href=\"UTD.htm?32/7/32892\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Reactive thrombocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of other MPDs (eg, PV, PMF, CML) or myelodysplasia must be ruled out. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A revision of the WHO criteria for the diagnosis of ET [",
"    <a class=\"abstract\" href=\"UTD.htm?18/28/18890/abstract/77\">",
"     77",
"    </a>",
"    ], which takes the above issues into account, includes combinations of the following findings (",
"    <a class=\"graphic graphic_table graphicRef52174 \" href=\"UTD.htm?16/37/16988\">",
"     table 4",
"    </a>",
"    ), (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A consistently elevated platelet count",
"      <span class=\"nowrap\">",
"       &gt;450,000/microL",
"      </span>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef68110 \" href=\"UTD.htm?29/43/30390\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef68024 \" href=\"UTD.htm?20/49/21265\">",
"       picture 4",
"      </a>",
"      ) in the absence of causes for reactive thrombocytosis (",
"      <a class=\"graphic graphic_table graphicRef74148 \" href=\"UTD.htm?32/7/32892\">",
"       table 3",
"      </a>",
"      ) and (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Reactive thrombocytosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Normal iron stores, as evidenced by normal serum ferritin and normal red cell mean corpuscular volume (MCV). Requires the failure of iron replacement therapy to increase hemoglobin levels to the polycythemia vera range in the presence of decreased serum ferritin.",
"     </li>",
"     <li>",
"      Megakaryocytic hyperplasia on bone marrow aspiration and biopsy (",
"      <a class=\"graphic graphic_picture graphicRef67362 \" href=\"UTD.htm?24/34/25127\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Absence of the Philadelphia chromosome or the",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      gene rearrangement, as well as absence of peripheral blood, bone marrow, and karyotypic evidence for a myelodysplastic (MDS) disorder or PMF (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      While presence of the JAK2 mutation is highly specific for the diagnosis of a MPD (eg, PV, ET, or PMF), it is present in only about one-half of patients with ET and is absent in patients with reactive thrombocytosis (see",
"      <a class=\"local\" href=\"#H15\">",
"       'JAK2 mutation'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/1\">",
"      Tefferi A. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview. Mayo Clin Proc 1998; 73:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/2\">",
"      Schafer AI. Thrombocytosis. N Engl J Med 2004; 350:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/3\">",
"      Harrison CN. Current trends in essential thrombocythaemia. Br J Haematol 2002; 117:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/4\">",
"      Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108:3472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/5\">",
"      Kiladjian JJ, Elkassar N, Hetet G, et al. Study of the thrombopoitin receptor in essential thrombocythemia. Leukemia 1997; 11:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/6\">",
"      Taksin AL, Couedic JP, Dusanter-Fourt I, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 1999; 93:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/7\">",
"      El-Kassar N, Hetet G, Bri&egrave;re J, Grandchamp B. Clonality analysis of hematopoiesis and thrombopoietin levels in patients with essential thrombocythemia. Leuk Lymphoma 1998; 30:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/8\">",
"      Griesshammer M, Hornkohl A, Nichol JL, et al. High levels of thrombopoietin in sera of patients with essential thrombocythemia: cause or consequence of abnormal platelet production? Ann Hematol 1998; 77:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/9\">",
"      Hirayama Y, Sakamaki S, Matsunaga T, et al. Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. Blood 1998; 92:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/10\">",
"      Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997; 90:4031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/11\">",
"      Fialkow PJ, Faguet GB, Jacobson RJ, et al. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981; 58:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/12\">",
"      Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/13\">",
"      el-Kassar N, Hetet G, Bri&egrave;re J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood 1997; 89:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/14\">",
"      Janssen JW, Anger BR, Drexler HG, et al. Essential thrombocythemia in two sisters originating from different stem cell levels. Blood 1990; 75:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/15\">",
"      Chen GL, Prchal JT. X-linked clonality testing: interpretation and limitations. Blood 2007; 110:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/16\">",
"      Champion KM, Gilbert JG, Asimakopoulos FA, et al. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol 1997; 97:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/17\">",
"      Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999; 93:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/18\">",
"      Shih LY, Lin TL, Lai CL, et al. Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood 2002; 100:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/19\">",
"      Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107:4214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/20\">",
"      Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999; 61:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/21\">",
"      Rozman C, Giralt M, Feliu E, et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/22\">",
"      Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc 2001; 76:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/23\">",
"      Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol 2008; 83:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/24\">",
"      Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/25\">",
"      Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/26\">",
"      Bellucci S, Janvier M, Tobelem G, et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 1986; 58:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/27\">",
"      Gugliotta L, et al. Epidemiological, diagnostic, therapeutic, and prognostic aspects of essential thrombocythemia in a retrospective study of the GIMMC group in two thousand patients. Blood 1997; 90:348a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/28\">",
"      van Genderen PJ, Mulder PG, Waleboer M, et al. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 1997; 97:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/29\">",
"      Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med 1995; 123:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/30\">",
"      Reid MM, Saunders PW, Kernahan J. Myeloproliferative disease in children: a demographic study. J Clin Pathol 1988; 41:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/31\">",
"      Michiels JJ, Van Genderen PJ. Essential thrombocythemia in childhood. Semin Thromb Hemost 1997; 23:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/32\">",
"      Dror Y, Zipursky A, Blanchette VS. Essential thrombocythemia in children. J Pediatr Hematol Oncol 1999; 21:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/33\">",
"      Yang RC, Qian LS. Essential thrombocythaemia in children: a report of nine cases. Br J Haematol 2000; 110:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/34\">",
"      Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia 1995; 9:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/35\">",
"      Hasle H, Wadsworth LD, Massing BG, et al. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol 1999; 106:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/36\">",
"      Giona F, Teofili L, Moleti ML, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood 2012; 119:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/37\">",
"      Randi ML, Putti MC, Scapin M, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 2006; 108:3600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/38\">",
"      Teofili L, Giona F, Martini M, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007; 25:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/39\">",
"      Chistolini A, Mazzucconi MG, Ferrari A, et al. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica 1990; 75:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/40\">",
"      Kurzrock R, Cohen PR. Erythromelalgia and myeloproliferative disorders. Arch Intern Med 1989; 149:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/41\">",
"      Michiels JJ, van Genderen PJ, Jansen PH, Koudstaal PJ. Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Leuk Lymphoma 1996; 22 Suppl 1:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/42\">",
"      van Genderen PJ, Prins FJ, Michiels JJ, Schr&ouml;r K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol 1999; 104:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/43\">",
"      Michiels JJ, Abels J, Steketee J, et al. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985; 102:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/44\">",
"      Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993; 43:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/45\">",
"      Ruggeri M, Finazzi G, Tosetto A, et al. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 1998; 103:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/46\">",
"      Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/47\">",
"      Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67:2926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/48\">",
"      Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117:5857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/49\">",
"      Gangat N, Wolanskyj AP, Schwager SM, et al. Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer 2006; 106:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/50\">",
"      Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ. Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemost 1997; 23:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/51\">",
"      Ruggeri M, Rodeghiero F, Tosetto A, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 2008; 111:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/52\">",
"      Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/53\">",
"      van Genderen PJ, Budde U, Michiels JJ, et al. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 1996; 93:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/54\">",
"      Fabris F, Casonato A, Grazia del Ben M, et al. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 1986; 63:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/55\">",
"      Rolf N, Suttorp M, Budde U, et al. Essential thrombocythaemia in a teenage girl resulting in acquired von Willebrand syndrome with joint haemorrhage and menorrhagia. Thromb Haemost 2010; 103:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/56\">",
"      Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/57\">",
"      Emilia G, Sacchi S, Temperani P, et al. Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis. Leuk Lymphoma 1993; 9:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/58\">",
"      Randi ML, Barbone E, Zerbinati P, et al. Essential thrombocythemia following polycythemia vera: an unusual sequence. J Med 1996; 27:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/59\">",
"      Tefferi A, Silverstein MN, Hoagland HC. Primary thrombocythemia. Semin Oncol 1995; 22:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/60\">",
"      Cervantes F, Alvarez-Larr&aacute;n A, Talarn C, et al. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002; 118:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/61\">",
"      Cervantes F, Tassies D, Salgado C, et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991; 85:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/62\">",
"      Sterkers Y, Preudhomme C, La&iuml; JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/63\">",
"      Geller SA, Shapiro E. Acute leukemia as a natural sequel to primary thrombocythemia. Am J Clin Pathol 1982; 77:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/64\">",
"      Shibata K, Shimamoto Y, Suga K, et al. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation--a brief review of recent literature. Acta Haematol 1994; 91:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/65\">",
"      Beressi AH, Tefferi A, Silverstein MN, et al. Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med 1995; 155:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/66\">",
"      Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V&gt;F) mutation. Blood 2007; 110:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/67\">",
"      Griesshammer M, Heimpel H, Pearson TC. Essential thrombocythemia and pregnancy. Leuk Lymphoma 1996; 22 Suppl 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/68\">",
"      Pagliaro P, Arrigoni L, Muggiasca ML, et al. Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. Am J Hematol 1996; 53:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/69\">",
"      Picardi M, Martinelli V, Ciancia R, et al. Measurement of spleen volume by ultrasound scanning in patients with thrombocytosis: a prospective study. Blood 2002; 99:4228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/70\">",
"      Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/71\">",
"      Kadikoylu G, Onbasili A, Tekten T, et al. Functional and morphological cardiac changes in myeloproliferative disorders (clinical study). Int J Cardiol 2004; 97:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/72\">",
"      Dingli D, Utz JP, Krowka MJ, et al. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001; 120:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/73\">",
"      Altintas A, Karahan Z, Pasa S, et al. Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma 2007; 48:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/74\">",
"      Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 1986; 23:177.",
"     </a>",
"    </li>",
"    <li>",
"     Imbert M, Vardiman JW, Pierre R. Essential thrombocythaemia. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/76\">",
"      Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005; 130:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/77\">",
"      Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/78\">",
"      Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008; 112:231.",
"     </a>",
"    </li>",
"    <li>",
"     Iland H, Laszlo J, Murphy S. Essential thrombocythemia. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman LR, Berk PD, Berlin NI (Eds), Saunders, Philadelphia 1995. p.292.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/80\">",
"      Damaj G, Delabesse E, Le Bihan C, et al. Typical essential thrombocythaemia does not express bcr-abelson fusion transcript. Br J Haematol 2002; 116:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/81\">",
"      Tefferi A, Ho TC, Ahmann GJ, et al. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med 1994; 97:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/82\">",
"      Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/83\">",
"      Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/84\">",
"      Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107:4139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/85\">",
"      Gale RE, Allen AJ, Nash MJ, Linch DC. Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood 2007; 109:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/86\">",
"      Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/87\">",
"      Cheung B, Radia D, Pantelidis P, et al. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2006; 132:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/88\">",
"      Zhang S, Qiu H, Fischer BS, et al. JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera. Leuk Lymphoma 2008; 49:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/89\">",
"      Toyama K, Karasawa M, Yamane A, et al. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Br J Haematol 2007; 139:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/90\">",
"      Wong RS, Cheng CK, Chan NP, et al. JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia. Br J Haematol 2008; 141:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/91\">",
"      Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/92\">",
"      Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W&gt;L/K mutation in essential thrombocythemia. Blood 2008; 112:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/93\">",
"      Cerutti A, Custodi P, Duranti M, et al. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol 1997; 99:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/94\">",
"      Juvonen E, Ikkala E, Oksanen K, Ruutu T. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br J Haematol 1993; 83:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/95\">",
"      Jenkins RB, Tefferi A, Solberg LA Jr, Dewald GW. Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3. Cancer Genet Cytogenet 1989; 39:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/96\">",
"      Patel K, Kelsey P. Primary acquired sideroblastic anemia, thrombocytosis, and trisomy 8. Ann Hematol 1997; 74:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/97\">",
"      Thiele J, Zankovich R, Steinberg T, et al. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis--a critical evaluation of clinical and histomorphological data. Acta Haematol 1989; 81:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/98\">",
"      Stoll DB, Peterson P, Exten R, et al. Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome. Am J Hematol 1988; 27:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/99\">",
"      Mittelman F. The Third International Workshop on Chromosomes in Leukemia. Lund, Sweden, July 21-25, 1980. Introduction. Cancer Genet Cytogenet 1981; 4:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/100\">",
"      Teofili L, Martini M, Luongo M, et al. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. J Clin Oncol 2002; 20:4249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/101\">",
"      Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood 2004; 103:3547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/102\">",
"      Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood 2000; 96:3310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/103\">",
"      Mi JQ, Blanc-Jouvan F, Wang J, et al. Endogenous megakaryocytic colony formation and thrombopoietin sensitivity of megakaryocytic progenitor cells are useful to distinguish between essential thrombocythemia and reactive thrombocytosis. J Hematother Stem Cell Res 2001; 10:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/104\">",
"      Escoffre-Barbe M, Amiot L, Beaucournu P, et al. Spontaneous megakaryocytic colony formation does not discriminate between essential thrombocythemia and polycythemia vera. Am J Hematol 2006; 81:554.",
"     </a>",
"    </li>",
"    <li>",
"     Thiele J, Kvasnicka HM, Orazi A, et al. Essential thrombocythaemia. In: WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, Swerdlow SH, Campo E, Harris NL (Eds), WHO Press, Lyon 2008. p.48.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/106\">",
"      Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 2009; 6:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/107\">",
"      Santhosh-Kumar CR, Yohannan MD, Higgy KE, al-Mashhadani SA. Thrombocytosis in adults: analysis of 777 patients. J Intern Med 1991; 229:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/108\">",
"      Robbins G, Barnard DL. Thrombocytosis and microthrombocytosis: a clinical evaluation of 372 cases. Acta Haematol 1983; 70:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/109\">",
"      Custodi P, Cerutti A, Balduini CL. Which tests are most useful to distinguish between clonal and reactive thrombocytosis. Am J Med 1996; 101:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/110\">",
"      Messinezy M, Westwood N, Sawyer B, et al. Primary thrombocythaemia: a composite approach to diagnosis. Clin Lab Haematol 1994; 16:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/111\">",
"      Alexandrakis MG, Passam FH, Moschandrea IA, et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/112\">",
"      Emilia G, Marasca R, Zucchini P, et al. BCR-ABL rearrangement is not detectable in essential thrombocythemia. Blood 2001; 97:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/113\">",
"      Rice L, Popat U. Every case of essential thrombocythemia should be tested for the Philadelphia chromosome. Am J Hematol 2005; 78:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/114\">",
"      Dekmezian R, Kantarjian HM, Keating MJ, et al. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 1987; 59:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/115\">",
"      Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008; 111:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/116\">",
"      Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29:3179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/117\">",
"      Barbui T, Thiele J, Carobbio A, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood 2012; 120:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/118\">",
"      Cervantes F, Colomer D, Vives-Corrons JL, et al. Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features? Leukemia 1996; 10:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/119\">",
"      Koike T, Uesugi Y, Toba K, et al. 5q-syndrome presenting as essential thrombocythemia: myelodysplastic syndrome or chronic myeloproliferative disorders? Leukemia 1995; 9:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/120\">",
"      Eyster ME, Saletan SL, Rabellino EM, et al. Familial essential thrombocythemia. Am J Med 1986; 80:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/121\">",
"      Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 1998; 18:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/122\">",
"      Kondo T, Okabe M, Sanada M, et al. Familial essential thrombocythemia associated with one-base deletion in the 5'-untranslated region of the thrombopoietin gene. Blood 1998; 92:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/123\">",
"      Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004; 103:4198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/124\">",
"      Wiestner A, Padosch SA, Ghilardi N, et al. Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia. Br J Haematol 2000; 110:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/125\">",
"      Li J, Xia Y, Kuter DJ. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br J Haematol 2000; 111:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/126\">",
"      Teofili L, Larocca LM. Advances in understanding the pathogenesis of familial thrombocythaemia. Br J Haematol 2011; 152:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/127\">",
"      El-Harith el-HA, Roesl C, Ballmaier M, et al. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol 2009; 144:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/128\">",
"      Teofili L, Giona F, Torti L, et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica 2010; 95:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/129\">",
"      Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med 2012; 366:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/28/18890/abstract/130\">",
"      Tecuceanu N, Dardik R, Rabizadeh E, et al. A family with hereditary thrombocythaemia and normal genes for thrombopoietin and c-Mpl. Br J Haematol 2006; 135:348.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4491 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18890=[""].join("\n");
var outline_f18_28_18890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clonality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Childhood ET",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vasomotor symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Thrombosis and hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Disease transformation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Physical examination and laboratory results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnostic criteria of the PVSG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      JAK2 mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MPL mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sensitivity of progenitor cells to thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      WHO criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Reactive thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Familial essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Suspecting the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Making the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4491\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4491|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/16/24835\" title=\"figure 1\">",
"      Organiz heme malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/20/16719\" title=\"figure 2\">",
"      The Philadelphia chromosome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4491|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/25/17808\" title=\"picture 1\">",
"      Erythromelalgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/34/25127\" title=\"picture 2\">",
"      Ess thrombocythemia marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/0/22536\" title=\"picture 3\">",
"      Essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/49/21265\" title=\"picture 4\">",
"      Manual hematocrit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/43/30390\" title=\"picture 5\">",
"      Leukoerythroblastic blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4491|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/55/6013\" title=\"table 1\">",
"      Disease transformation in ET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/18/40235\" title=\"table 2\">",
"      Clin char ess thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/7/32892\" title=\"table 3\">",
"      Causes reactive thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/37/16988\" title=\"table 4\">",
"      Proposed criteria for ET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/43/41659\" title=\"table 5\">",
"      Proposed criteria for PV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/59/25531\" title=\"table 6\">",
"      Diagnostic criteria MMM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/8/26764\" title=\"table 7\">",
"      Proposed criteria for PMF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/33/21020\" title=\"table 8\">",
"      FAB classification of MDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=related_link\">",
"      Approach to the patient with thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=related_link\">",
"      Biology and physiology of thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39720?source=related_link\">",
"      Classification of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14905?source=related_link\">",
"      Cytogenetics and molecular genetics of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=related_link\">",
"      Diagnostic approach to the patient with suspected polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=related_link\">",
"      Prognosis and treatment of essential thrombocythemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_28_18891="AAST-OIS for the esophagus";
var content_f18_28_18891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Association for the Surgery of Trauma Organ Injury Severity Score (AAST-OIS) for the esophagus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Injury description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        I",
"       </td>",
"       <td>",
"        Contusion; hematoma; partial thickness laceration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        II",
"       </td>",
"       <td>",
"        Laceration &le;50 percent of circumference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        III",
"       </td>",
"       <td>",
"        Laceration &gt;50 percent of circumference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        IV",
"       </td>",
"       <td>",
"        Segmental loss or devascularization of &le;2 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        V",
"       </td>",
"       <td>",
"        Segmental loss or devascularization of &gt;2 cm",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Advance one grade for multiple lesions up to grade III.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore EE, Jurkovich GJ, Knudson M, et al. Organ injury scaling VI: Extrahepatic biliary, esophagus, stomach, vulva, uterus (nonpregnant), uterus (pregnant), fallopian tube, and ovary. J Trauma 1995; 39:1069. Copyright &copy; 1995 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18891=[""].join("\n");
var outline_f18_28_18891=null;
var title_f18_28_18892="Warfarin dosing protocol";
var content_f18_28_18892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested protocol for initiating warfarin therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"4\" width=\"15%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Days of warfarin treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        INR &lt;1.5",
"       </td>",
"       <td class=\"subtitle1\">",
"        INR 1.5 to 1.9",
"       </td>",
"       <td class=\"subtitle1\">",
"        INR 2.0 to 3.0",
"       </td>",
"       <td class=\"subtitle1\">",
"        INR &gt;3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Suggested initial dose for days 1 and 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal adult",
"       </td>",
"       <td>",
"        5 mg*",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frail adult, malnourished, elderly, liver disease",
"       </td>",
"       <td>",
"        2.5 mg*",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Dosing for day 3 and beyond",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Day 3",
"       </td>",
"       <td>",
"        5 to 10 mg",
"       </td>",
"       <td>",
"        2.5 to 5 mg",
"       </td>",
"       <td>",
"        0 to 2.5 mg",
"       </td>",
"       <td>",
"        No dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Day 4",
"       </td>",
"       <td>",
"        10 mg",
"       </td>",
"       <td>",
"        5 to 7.5 mg",
"       </td>",
"       <td>",
"        0 to 5 mg",
"       </td>",
"       <td>",
"        No dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Day 5",
"       </td>",
"       <td>",
"        10 mg",
"       </td>",
"       <td>",
"        7.5 to 10 mg",
"       </td>",
"       <td>",
"        0 to 5 mg",
"       </td>",
"       <td>",
"        No dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Day 6",
"       </td>",
"       <td>",
"        7.5 to 12.5 mg",
"       </td>",
"       <td>",
"        5 to 10 mg",
"       </td>",
"       <td>",
"        0 to 7.5 mg",
"       </td>",
"       <td>",
"        No dose",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    In this protocol, which is provided for guidance only, suggested doses of warfarin after day 2 are given as ranges. The clinician must judge the rapidity and magnitude of INR changes for the individual patient and make dosage adjustments accordingly. An algorithm for monitoring and adjustment of maintenance warfarin is presented separately. Refer to UpToDate topics on use of warfarin and table on suggested protocol for adjustment of maintenance warfarin.",
"    <div class=\"footnotes\">",
"     n/a: not applicable.",
"     <br/>",
"     * This table assumes that the patient has started with an INR in the normal range.",
"    </div>",
"    <div class=\"reference\">",
"     See text for details concerning the source for this protocol and relevant references.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18892=[""].join("\n");
var outline_f18_28_18892=null;
var title_f18_28_18893="NHL in transplant recipients";
var content_f18_28_18893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incidence of non Hodgkin lymphoma in transplant recipients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 242px; background-image: url(data:image/gif;base64,R0lGODlhswHyANUAAP///4CAgAAAAEBAQP+AgP/AwMDAwP8AAAAz/0Bm/8DN/xBA/4CZ//Dz//9AQHBwcNDZ///w8DBZ/2CA/6CgoCAgINDQ0DAwMP/g4KCz/+Dg4BAQELDA/7CwsHCN/1BQUCBN/+Dm//Dw8JCm///Q0P+goGBgYP8QEP8gIFBz//8wMJCQkP+wsP9gYP9QUP+QkP9wcAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACzAfIAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaZHIgYaRhoGrqqnsbKzAAYfAgFGAQK8uLS/wJ+9uUW7Jq6rwcrLlrvERLsVAwEiRAYB2NkGzNzdgs5GFA8BFQIP1tnY097s7XngSAYCA0rY7vf4bwYmAse1vh9MkPOVxF6+gwjL9OL1L1eADQI2nKv3LKHFi3QMYtzIkY3GjiBDivkosqRJLCRPqlzpJCXLlzChVYxJE6bLmjhL3szJk+PO/55AE/4MSvTe0KJIux1NyjTY0qZQZT2NSpXU1KpYP13NylXT1q5gK30NSxbS2LJoF51Ny9bQ2rZwA72NS5cJBQpu5tbde+QDvTZ6+QoWQqHCKwtnrgVYZ4YDh8FZByz8W0Yx4zIcFjSAXJVCOrxpAj+ZkICzaZQzxzQAMeJ0UwoQeVE+I/oJBAQQXCetUG7ABhNqaj9hIEE3UgEdBAB4ADx06jIJPBgnKsDAhQB+gz8nE2KBgulALwjkNRGNcCgZNIMPumLFmvNQUqRYz7NDAA0BEDtvszoD/ZoP8GJLc+ZtZ4YCC4TwX0y/XXDNbGbAF4UHxS34UnUD7ANhGRJGIf8BAxayNMAFFdzi3n5vQOBdiCpZENsF1aD4xgggbMbiSQbop50cCUxwY0kCJfOegWk0sMBjP4IkmQAfgCYjHJkpmGRHHZgAkURCckikGh6UNiVHVU5WIB0NSNDalxcteQEFGogzJh235YZmQiY8kOWTchBn45xodXhFdHym5acV3X0XKFmDWpHZnod6Y4GOW8iz4RGJWiFfo+0MMKkVS25azJZurHYmptx0cEEXFqwwzxGKZXPZHQjKSeoyS8qmhaSsprMYqG8QNyszD2iqaXlX4MpEpVh8+GtMxi6B7BUqGrosLRZcUF0FJ15Ra3XO8goHjYxOe8oFG2xgQLBZWPD/igExFuQtHJeKKwtyGS62Yx9GIimvKRusMEAHFRBI27twICjlvlYttA2ee3SJsCn+ftDBkICUCeLDo6QC6Zt/xIlxKBT0AuO9gIwgQbgfa7JBBQEEKHCEBM8BaMqdmCsEugz30Z2+NGfSsismfJAjx4Es2rMm29o6cCGkHZ2JZ7o6qWUhojqtU8x1xGp1SM+G4evWHXUdhgTSgb2R2GAUajYkjD3wAcmGZFDj2ozgJw02F3gaBtphxEt3IvIsRBDRhhjp39+IpCKeKxvDvIjBiCuiLuNwI+Jw5IcE2IveYPA9hrKYFxJRNlI7zojHoQ/Ccl5Y8wFu6oIEe1hi6rTO/0ePsAeyLedcWGb7Hobn/gfU2JQ+9SPpySr8Hqk0XzkjyS+/R8jVXUCs6ZBELz0eFZD44PONjJDg9ndgeC7vXniexgQnk19HwNdJBL4j7KPsfhvJ8bLBncdTUv/9crBAAFbAv/5RIgFeAqAbPnAqDWzgd1VQ3xrK5CMFtgE5N0NfFyQ4QQlU0IJqwOByNMgFDnbwgyA8wwckEqBsLS0T3RlVCstggXIIYGQ5o4SKDjdDMwyNYpvYYQ/JoCnWdUKIQ9wbCb9gwjdoL4leCJCwrmfATTwRilvY3fwwcUUsIqKJcRDfwbx4BREEywIS22Im/kfGK9yiOkFT4xrb18YqCP/AX9/LISfYWEcp0MsAA3ibHjmBwD5OwUorE4DxyABGMnnQkFEQwS3kB4UO+OUB7RJCqwKwMCQ00pEohCQY5GG9VUFjIUT6JChF2YRqRYSKSuAHXsqRJXh0KxYxZOUSemOtd0lmG788pWyytMldyQKJujyCCLPjhGAGcwgG6IAtmISOdLzKFMhMJjRAE4CXxVKRAKBlKlaRjOToTZV3yKY2AZA0Uy6BlFJsCDulwYuJuesXXUxmsIQ1LCdYcgCYBIAFBoCXf6aRIsDI5zo9AkEuLkB5C2WoMsQYUSMqg48VHeQpMKpLDRSQkQ3dBEdFKalOYm8ZhdSmCBZzR8IFg4L/63wUAD7auZByAqbJLKJGZ4FTVurUpcvIZSQgwACetaUV68qbHH+hzkOEgANdQgAIJrCAFIxRUIJz5wvb0dRAKGAEKQABAhJQVBs1wAMLkCFaKMDPfu4UGCrygAIgqocQZCCqHhwBXYegABAkYK/iQmchMkAasfqVASNQwFXfoAAGpGABCyCrAuyHBAYggAGUxQpS19U4kF5EARxgAGkWgAAJkDWxmf0CBO4qgdJOIAOAbUIIEgACaYFlF4JbohYECwnQOjYBCBhrChiQgclyoQGNTQBkh2tbLIhvAql9jabK5VaghgS5GfhtcHtU1OY2YbXsK60HMrDYLTTgsUbl/8pPl1qSEHyVAQlobWQnUFS6NiC0wAVBChKLBg74tbxUWe9bX+LeEXTJsNGZgFijwwEAl+Gsac0KW32zgepuFSoQaCx/56AACUggtkTBrZgGHCgGLMAD0eXJZmdH4kDNtraN4i1Z0pOCFNNkwvyE5Shr17PzLoCHIc6qbq3gO6f1NQEOzgnAbmjSk46hACVwDYQvFhQNTHKRVRRDAVSAAgJE4DQQ8LB3adIBiARUomgogAtO0AIMnEZ8KOaJiDfHXi9goAUncEEBTPPi9L4Ex1Os8xciQAAUqGDPnMlMjS3UxBIgmjMNoKpak4BcOWXYxnK4nFRsqgUom+bISRaCAv/GKgTgjpkJwDVCqsOw6iaMmsrN4HQWttzlLw+mAZaF9RFG7SVTAyAEpJlAboCNwDgTl6h9vay0ks0ABTR2tYolTXQ2k10OyEdOIyi2XZvdo82suks9yk1jOUCax0xgrLqeBDrVzGY3DwYCtD01AEYNAgYwQKyKXcCHIDtvsp7bRwggLQLSM1YeEjwB2Q24sv2NAB/lt7UgAMC5PUAcBQB3Ah5AwHxWXW+0RtyykQ1uCCCeQLHImgt3zvOj+QJn+406uDD/asPhi4DvEBa4pSntEFq9cwQIwbL6ujmpV91aAKRA480GANF9vmoFdIm0ALDsdzLu7Mv67ORdILShV17/lxCg1wi8LnXNLUtfe4cg43IlNanFrmqfR73mQkB72Fed6ki3FgEcoDvTfc4BjXOg6FJ/e9XTrW6sf8HRiU5v2JVe89tIgANOhzfeM6D2BAKXA8q7PFHhzngOUL40epd4YjOe7ZqPQOOMf3tRxSp4wY86BX6OhIyR4GnXLN7Xfw+uBEKgorFWfgiZQYAMgz+CwAOg9zhPfepNHHDp5Hes3vZ5maTK+sAHHrgLwMTsj0BrLwOQ504xPBnY3Wb3gR8Y21dCyvWcUZMbQuuHvkgBCEB/FhTA1ilLvxMQv4z50///AIho/gcDDqACB3AAKuAAMMB1akAAUUYEJUAAfTB//+4WCvoXBSzwgKRQAFBGAAIIgCDogUkQAQXAAiIIAPPnaAzYaQfgAADAAggYAQpYBA5wAFlQAg5AAmFAAAewgkgwg7Infm7AAijQZSHog4hAAvP3gQ7gAChwgCjQhCfIBfPXhE94AFHoACeYghwoBQXQghhwAifgZgWggwCAAQTwAgZ4hgWAARFYgRFYAhFAgjpIh0MQAS1wAC9AAiSIARGggybogF+GAW34hkJAAvUXAYQYAS/wAl/Gg3uGiGnoZoTohgTgZiSAgPdnFkL4BiUAA0coBP4XgvT3gSroBRwYgR9IiqUoiv9HgE8YhQvoiqe4Bqm4hQRghVAohUgoiv8taIAsIAQtCAAkIIYOcAI2yIPIeAAnMIcqcAI1qAIAcAIoAAAloIdD8IUH6ABfaIAu+IvDqIwH2IwvgIA1OH9YGI0AAIkAUIA12IziyIwyeIA9yImaMIqkyIROuItauIqsqI9XmIW4yIoDWYpmSAi32IsoSI/SKIwumId7VoPreABR5gI9eI0eaJEkkIckYJH4N5F79oV6poMkYIJPOJEV2YM1+AJtSGj1yJHsSIi52IM8mJJ7NoxBqAwJ6YoEaYpd2A1fKIbYCADDKJHtmIz1CIk8mIBNSAKZaJEtUATs+IUSSIzUCAMnyY6QSAJXeAKImJQ02YMR8IwtcI5aWY//OGmPKfSF3HiAOjiMEDmWSLlnkAiDLfBlLOBmVxiMRMCDLECCB1CVfimXIAmSexgBMBCYkCiXLsmBBwADAACRZ3mT0viRzOMZFJBJntSJGMOWE4kCETCMYTiOc1mYiUmPOliO1VgE2tiWVVmMpFmYkGiRB6gCLkmPUbaYBsiMYUmX9ViD9egH1iIZp3JLKWSHKNiGZSgEfaiEbDiImwgAJBid5ViVRVCJfTgEleici/icxLicE2l/7taddLiI3dmdyfkHyfE2t2BP99R+SfCEFQgG7HgJ4GBLmqQrmqIr/Nmf/vmfABqgAjqgBFqgBnqgCJqgCrqgDKoNZwCeYoCe/83gC/hZC/o5DQi6nweqoRuKoQbKoR/qoSGaoSJaoCBqoiU6oCdKoCsqoNeUFapyDi1knFHwFWNho61zo1ijo1OAoz26o5wpEhogAIZBSzQKBT4qBUlaozkKpD/6pEwKpUgapCJRGESKZTIxBa6gpK2zpVEqBV76pVAQplOqpU3WBGNBpi1BpUDRNW7KpkPwphc2BhcoFHAKAHI6pyNxp3lqGmoqBn8aBoEqqGdKqIlRqKOEqPC5qIzaqI76qJAaqZKaRCKAmZoZBupiBgIUAFjKBanCqZcKBq3QWV2QCiw2BpVap/cwnDdEBm0CEWawEDrGBSOGqsNJBoGjNGLgIv/zUAGDsZ4A0J502gtmgBcWwBBjgBdDqhxkoDlDBqZM9kNiUA6kGhf3OThigKxmMKS+iqsBQqXysAvPGgXyUGEmQFNacKy8QU2Cca1sqq1lIKxkwFbmgKoV8ADNgqkCQZxjQErWAU58EaPL0VJkAK9iIAKS0ale8EyjlFtnYLBecKz0UKFxwa0GYKRi0AoCgq5ZoAHDiQ0cWyzXoTkhawWmqioXUK279QEsNa5QUA6mwi2CYaUVoLBZMGdBmqsCkrHWQqTu2a9aBQZLxiShiirWsgE2O6lKu7RM27RO+7RQG7VSO7VUW7VWe7WpgwxCoC4li7XMIK4AIALlUrReyw6rIgCzu+AeKxVI9rRPJoAY12ABFLAN/gJQXVu2l5Ac5VCc5BIA1oIYLPMAK4OnEYEL/DAODoK3pbAkiCGx3eQL5wOru2BPt8Cyiqq4nGAskqIN6xmzhLswImACPfuzmPsJzVIuc7sCnoELS/a5QmACK3AuBFu6oNAsaMQLFdABImAt6+q6eHols0q7wju8xFu8xnu8yJu8yru8zNu8zvu80Bu90ju91Fu9gxAEADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yearly incidence of non-Hodgkin lymphoma after transplantation in heart and kidney transplant recipients over time. The risk is greatest with higher degrees of immunosuppression: in the first year and in heart transplant recipients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Opelz, G, Henderson, R, for the Collaborative Transplant Study, Lancet 1993; 342:1514.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18893=[""].join("\n");
var outline_f18_28_18893=null;
var title_f18_28_18894="Hook of hamate fracture";
var content_f18_28_18894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fracture of the hook of the hamate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The carpal tunnel or 45 degree supination oblique view was used in this radiograph of the wrist in order to isolate the image of the hook of the hamate from the shadows of other carpal bones. In this view, a fracture of the hook of the hamate is easily seen (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18894=[""].join("\n");
var outline_f18_28_18894=null;
var title_f18_28_18895="capillary nail loop c";
var content_f18_28_18895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple areas of capillary loop dilatation in a patient with dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H. Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_28_18895=[""].join("\n");
var outline_f18_28_18895=null;
